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"Let thy food be thy medicine and thy medicine be thy food."  
Hippocrates (460-377 B.C.)  
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SUMMARY 
 
Introduction: Resveratrol a natural occuring polyphenol present in red wine, 
peanuts and grapes, has been reported to exhibit a wide range of biological and 
pharmacological properties. In addition to cardioprotective and antiinflammatory 
effects, potent chemopreventive activities of resveratrol and its analogs in 
various carcinogenesis models are described and there has been a great deal 
of experimental effort directed toward defining these effects. We and others 
could previously demonstrate that resveratrol inhibits cell growth in several 
malignant cell lines via modulation of polyamine metabolism. In detail, 
resveratrol was shown to simultaneously inhibit biosynthetic ornithine 
decarboxylase (ODC) and activate catabolic spermine/spermidine 
acetyltransferase (SSAT). One aim of this work was to specify the underlying 
molecular mechanisms of resveratrol actions in colorectal cancer cells and 
especially to identify possible roles of transcription factor peroxisome-
proliferator activated receptor γ (PPARγ) and the sphingolipid metabolite 
ceramide.   
Previous studies could demonstrate that ursolic acid (UA), a pentacyclic 
triterpene found in berries and plants, has antiproliferative as well as 
proapoptotic activities on cancer cells. The objective of this second project was 
to elucidate the underlying molecular mechanisms of these chemopreventive 
effects. 
Methods: The colorectal cancer cell lines Caco-2, HCT-116 and HT29 were 
cultured under standard conditions and were treated with miscellaneous agents 
for different time intervals. Cytotoxicity was excluded by commercial kit 
measuring lactate dehydrogenase activity in the supernatant of damaged cells. 
Cell growth was determined by BrdU incorporation and crystal-violet staining. 
Protein levels were examined by Western blot analysis. The activity of the 
enzyme SSAT was assayed with a radiometric technique measuring the amount 
of synthesized [acetyl-14C]-spermidine. ODC activity was also assayed 
radiometrically measuring [14CO2]-liberation. Ceramide concentrations were 
detected by HPLC-coupled mass-spectrometry. A dominant-negative PPARγ 
mutant was transfected in Caco-2 cells to suppress PPARγ-mediated functions. 
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PPARγ ligand dependent transcriptional activity was measured via a luciferase 
assay. Apoptosis induction was detected by measuring DNA fragmentation. 
Caspase-3 induction was determined via an activity assay. 
Results: Resveratrol [30-200 µmol/L] inhibits cell growth both in Caco-2- and 
HCT-116 cells in a dose- and time-dependent manner. In contrast to Caco-2-
wildtype- resveratrol failed to increase SSAT activity in dominant-negative-
PPARγ-cells. PPARγ involvement was further confirmed via ligand dependent 
activation as well as the induction of specific PPARγ-dependent target 
Cytokeratin 20 after resveratrol-treatment. Resveratrol further increases the 
expression of PPARγ coactivator PGC-1α as well as SIRT1 in a dose-
dependent manner after 24h of incubation. Co-incubation with SB203580 
abolishes SSAT activation significantly in both cell lines. The involvement of 
MAPK p38 was further confirmed by a resveratrol-mediated phosphorylation of 
p38 protein in both cell lines. Resveratrol further increases the expression of 
PPARγ coactivator PGC-1α as well as SIRT1 in a dose-dependent manner.  
Moreover, the antiproliferative effects of resveratrol closely correlate with a 
dose-dependent increase of endogenous ceramides. Compared to controls the 
cell-permeable ceramide analogs C2- and C6-ceramide significantly inhibit 
ODC-activity in Caco-2 and HT29 cells. C6-ceramide further diminished protein 
levels of protooncogenes c-myc and ODC, which is strictly related to the ability 
of ceramides to inhibit cell growth in a time- and dose-dependent manner. 
These results were further confirmed using inhibitors of sphingolipid 
metabolism, where only co-incubation with a serine palmitoyltransferase 
inhibitor could significantly counteract resveratrol-mediated actions. These data 
suggest that the induction of ceramide de novo biosynthesis but not hydrolysis 
of sphingomyelin is involved in resveratrol-mediated inhibition of ODC. The 
relevance of intracellular polyamine depletion was further confirmed by 
exogenous polyamines which could counteract the growth inhibitory effects 
mediated by resveratrol. In contrast to the regulation of catabolic SSAT by 
resveratrol, inhibitory effects on ODC occur PPARγ-independently, indicating 
independent pathways of resveratrol-action. 
We could also show, that treatment with UA leads to a significant time- and 
dose-dependent cell growth inhibition of Caco-2, HCT-116 as well as HT29 
cells, coincident with the upregulation of the cell cycle regulators cyclin E, 
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p21WAF1/Cip1 and p27Kip1. In addition, UA significantly induces apoptosis, which is 
mediated by an increase of BAX/Bcl-2-protein-ratio as well as an upregulation 
of TRAIL protein which meets in an induction of caspase-3 activity. 
Furthermore, we could show that UA leads to a PPARγ-dependent induction of 
SSAT but in contrast to resveratrol does not inhibit biosynthetic ODC activity. 
Conclusions: On the basis of these findings, p38 MAPK as well as 
transcription factor PPARγ can be considered as molecular targets of 
resveratrol in the regulation of cell proliferation and SSAT activity respectively in 
a cell culture model of colon cancer. Moreover, the results provide evidence for 
the involvement of ceramide de novo biosynthesis in resveratrol mediated 
inhibition of ODC activity. 
The observed reduction of cell growth of colon cancer cell lines after treatment 
with ursolic acid presumably results from a large increase in the number of 
apoptotic cells. The induction of the catabolic enzyme SSAT via PPARγ-
dependent mechanisms therby seems to present the major molecular target in 
the induction of programmed cell death. 
Due to these results the phytochemicals resveratrol as well as ursolic acid could 
show great chemopreventive and therapeutic potential in the treatment of 
colorectal cancers.  
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ZUSAMMENFASSUNG 
 
Einleitung: Resveratrol (3, 4‘, 5-Trihydroxy-trans-stilben) ist ein natürlich 
vorkommendes Polyphenol, welches vorwiegend in Trauben, Erdnüssen und 
Rotwein zu finden ist. Neben kardioprotektiven und antiinflammatorischen 
Wirkungen werden Resveratrol auch verschiedene chemopräventive 
Eigenschaften zugesprochen. In früheren Untersuchungen konnten wir bereits 
zeigen, dass Resveratrol die Hemmung des Zellwachstums in kolorektalen 
Karzinomzellen, zumindest teilweise, über die Modulation des 
Polyaminstoffwechsels vermittelt, zum einen über die Hemmung der 
bisynthetischen Ornithin Decarboxylase (ODC) und zum anderen über die 
Aktivierung der katabolen Spermidin/Spermin-Acetyltransferase (SSAT). Ein 
Ziel unserer weiterführenden Untersuchungen war es nun, die molekularen 
Mechanismen dieser Resveratrol-vermittelten Effekte genauer zu 
charakterisieren. Von besonderem Interesse waren dabei die mögliche 
Beteiligung des nukleären Transkriptionsfaktors Peroxisom-Proliferator 
aktivierter Rezeptor γ (PPARγ), sowie der Ceramide, eine zu den Lipiden 
zählende Untergruppe der Sphingolipide. 
Die Ursolsäure (UA) ist ein pentacyclisches Triterpen, das überwiegend in 
Beeren, Früchten, Kräutern und der natürlichen Wachsschicht von Äpfeln und 
Birnen zu finden ist. Neben antiinflammatorischen und hepatoprotektiven 
Wirkungen weisen epidemiologische Untersuchungen auch auf 
chemopräventive Effekte der UA hin. Ein weiteres Ziel war es daher, auch die 
molekularen Mechanismen dieser Effekte näher zu charakterisieren 
Methodik: Die kolorektalen Karzinomzelllinien Caco-2, HCT-116 und HT29 
wurden unter Standardbedingungen kultiviert. Die Zellen wurden über definierte 
Zeiträume mit steigenden Konzentrationen verschiedener Substanzen inkubiert. 
Zytotoxische Wirkungen der eingesetzten Konzentrationen wurden in 
Vorversuchen mittels eines Zytotoxizitätstestes (Messung der Laktat 
Dehydrogenase-Freisetzung) ausgeschlossen. Die Zellzahl wurde anhand des 
BrdU Einbaus in die DNS, die Zellzahl mittels Kristallviolettfärbung ermittelt. 
Verschiedene Proteine wurden durch Western Blot Analyse dargestellt und 
densitometrisch ausgewertet. Die Aktivität der SSAT wurde mittels [Acetyl-14C]-
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Spermidin-Bindungsassay quantifiziert. Zur Aktivitätsbestimmung der ODC wird 
radioaktiv markiertes Substrat zum Zelllysat gegeben und die Freisetzung von 
[14CO2] gemessen. Zur Hemmung der PPARγ-vermittelten Funktionen wurde 
eine dominant-negative Mutante in Caco-2-Zellen transfiziert. Die 
Ceramidbiosynthese nach Resveratrol-Inkubation wurde mit HPLC-
Massenspektrometrie erfasst. Die Ermittlung der Liganden-bindungsabhängigen 
PPARγ-Promotoraktivität erfolgte mittels Luziferase-Assay. Die Erfassung der 
Caspase-3-Aktivität sowie der DNA-Fragmentierung mittels ELISA dienten als 
Marker der Apoptose-Induktion. 
Ergebnisse: Resveratrol [50-200µM] führte sowohl in Caco-2- als auch in HCT-
116-Zellen zu einer zeit- und dosis-abhängigen Hemmung der Zellproliferation 
sowie einer Reduktion der Zellzahl. Resveratrol führte signifikant zu einem 
Anstieg der SSAT-Aktivität nach 24h sowohl in Caco-2-Wildtyp, als auch in 
Caco-2-Nullvektor-Zellen, während keine Effekte detektiert werden konnten, 
wenn die PPARγ-vermittelten Effekte unterdrückt sind. Eine Beteiligung von 
PPARγ konnte zudem durch die Liganden-abhängige Promotoraktivierung, 
sowie durch die Induktion des spezifischen PPARγ-Targets Cytokeratin 20 
bestätigt werden. Zudem führte Resveratrol dosisabhängig zur 
Expressionssteigerung des PPARγ Coaktivators PGC1α sowie SIRT1 nach 24h 
Inkubation. Co-Inkubation mit dem spezifischen MAPK p38 Inhibitor SB203580 
wirkte signifikant der Resveratrol-induzierten SSAT-Aktivierung entgegen. Eine 
Aktivierung von p38 konnte weiterhin durch einen Anstieg von phosphoryliertem 
p38 auf Proteinebene nachgewiesen werden.  
Koinzident mit der zeit- und dosisabhängigen Zellwachstumshemmung führt 
Resveratrol signifikant zu einem Anstieg der intrazellulären 
Ceramidkonzentration in kolorektalen Karzinomzellen. Im Vergleich zur 
Kontrolle hemmt das membrangängige Ceramid-Analogon Hexanoylsphingosin 
(C6) signifikant die Expression der Protooncogene c-myc und ODC, sowie 
zusätzlich die ODC-Enzymaktivität in  Caco-2 und HT29-Zellen, was signifikant 
mit einer dosisabhängigen Hemmung des Zellwachstums durch Ceramide 
korrelierte. Darüber hinaus führte die Co-Inkubation mit 
Ceramidsyntheseinhibitoren zu einer signifikant Verminderung der Resveratrol-
induzierten Effekte, was auf eine Induktion der Ceramid-Neusynthese durch 
Resveratrol, nicht aber auf eine Hydrolyse von Sphingomyelin schließen lässt. 
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Im Gegensatz zur Aktivierung der SSAT erfolgte die Hemmung der ODC durch 
Resveratrol PPARγ-unahbängig.  
Weiterhin konnten wir zeigen, dass UA [10-30µM] zu einer signifikanten zeit- 
und dosisabhängigen Hemmung der Zellproliferation, sowie einer Reduktion der 
Zellzahl von Caco-2-, HCT-116- und HT29-Zellen führt, was mit einer deutlichen 
Expressionssteigerung der Zellzyklusregulatoren Cyclin E, p21WAF1/Cip1 und 
p27Kip1 korreliert. UA führte zudem koinzident zu einer dosisabhängigen 
Expressionssteigerung von TRAIL, sowie einem gesteigerten BAX/Bcl-2-
Protein-Quotienten, was wiederum in einer gesteigerten Caspase-3-Aktivität 
und darauf folgender DNA-Fragmentierung resultiert. Weiterhin konnten wir 
zeigen, dass die Inkubation mit UA zu einer PPARγ-abhängigen SSAT-
Aktivierung führt, im Gegensatz zu Resveratrol aber nicht gleichzeitig auch die 
Aktivität der ODC hemmt. 
Schlussfolgerung: Unsere Ergebnisse weisen darauf hin, dass sowohl die 
Aktivierung der p38 MAPK, als auch des Transkriptionsfaktors PPARγ 
essentielle Ereignisse für die Resveratrol-vermittelte Induktion der katabolen 
SSAT darstellen. Des weiteren scheint die Aktivierung der de novo 
Ceramidbiosynthese entscheidend an der Resveratrol-induzierten ODC-
Hemmung beteiligt zu sein.  
Weitere Daten lassen darauf schließen, dass die wachstumshemmenden 
Effekte der Ursolsäure überwiegend durch Zunahme apoptotischer Zellen 
vermittelt werden. Die Apoptose wird dabei sowohl über extrinsische, als auch 
intrinsische Signaltransduktionswege induziert, wobei die PPARγ-abhängige 
Aktivierung der SSAT eine zentrale Rolle einzunehmen scheint.   
Diese in vitro Daten weisen auf potente chemopräventive und –therapeutische 
Eigenschaften der natürlichen Pflanzeninhaltsstoffe Resveratrol und Ursolsäure 
hin und könnten daher vielversprechende Kandidaten in der Entwicklung neuer 
Therapiekonzepte in der Behandlung des kolorektalen Karzinoms darstellen.  
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1 INTRODUCTION 
1.1  Colorectal Cancer 
 
 
Figure 1:  Adenoma-Carcinoma-Sequence 
Colon cancer results from a series of pathologic changes that transform normal 
colonic epithelium into invasive carcinoma. Specific genetic events, shown by 
vertical arrows, accompany this multistep process [modified from Jänne [1]] 
 
Colorectal cancer (CRC) accounts for approximately 10–15% of all cancers and 
is the second leading cause of cancer-related death in Western countries with 
an estimated 71400 new cases and 28868 deaths in Germany in 2002 [2] and 
153760 new cases and 52180 deaths in the United States in 2007 [3]. As with 
many other cancers, the development of colorectal cancer typically results from 
a complex interaction between genetic and environmental influences. 25% of 
patients with colorectal cancer have a family history of the disease, which 
suggests the involvement of a genetic factor. Such inherited colon cancers can 
be divided into two main types: the well-studied but rare familial adenomatous 
polyposis (FAP) syndrome, which accounts for approximately 1% of cases of 
colon cancer annually, and the increasingly well-characterized, more common 
hereditary nonpolyposis colorectal cancer (HNPCC), which accounts for 5% to 
15% of cases [4-7]. The remaining 75% of colorectal tumors develop 
sporadically or are caused by environmental or lifestyle factors such as physical 
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inactivity [8], obesity [9], smoking [10], alcohol consumption [11], a diet high in 
red meat [12], and inadequate intake of fruits and vegetables [13]. The World 
Cancer Research Fund estimates that 50% of colorectal tumors are avoidable 
through nutritional modifications [14;15]. 
The earliest model of pathogenesis of colorectal cancer - the adenoma-
carcinoma hypothesis [16], is now widely accepted. It proposes that the initial 
colorectal lesion arises as a benign adenomatous polyp that later undergoes 
further disorganisation of cellular and tissue phenotype. Some earlier stages in 
the process have also been proposed: hyperproliferation of the upper crypt cells 
leading to the formation of aberrant crypt foci and microadenomas [17]. 
Vogelstein and colleagues [18-20] have provided a molecular basis for the 
adenoma-carcinoma sequence by describing the complex multistep process in 
which cells accumulate alterations of multiple genes that control cell growth and 
differentiation, resulting in the neoplastic phenotype (Figure 1). 
Mutations in at least four or five genes are required for formation of a malignant 
tumour [14]. The first events inactivate the APC (adenomatous polyposis of the 
colon) gene (also the cause of FAP) in both chromosomes. APC is a tumor-
suppressor gene, and when mutation eliminates its function cells are 
immediately launched on the pathway toward malignancy. This is followed by 
mutation in the oncogene K-ras and further mutation of the tumor suppressor 
genes SMAD4 and p53 [21]. Other genetic events also play a role, for example 
modulation of DNA methylation in CpG sequences of the promoter regions of 
tumor-suppressor and DNA-repair genes leading to inactivation or DNA 
amplification as a mechanism of oncogene activation [22]. These genetic 
alterations are associated with the development of preneoplastic lesions 
(aberrant crypt foci, polyps, adenomas) which can develop into carcinomas [23]. 
Up to 10% of all sporadic cancer types feature an additional pattern which is 
characterised by development of deficient DNA repair; this leads to genetic 
instability and, therefore, to an increased rate of mutations, prevalently in the 
oncogene K-ras [24]. 
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1.2   Chemoprevention 
 
Table 1 Causes of Death 1980-2003 (USA) 
 
Epidemiological data accumulated over the last 20 years show a significant 
decrease in the death rate within the US due to heart, cerebrovascular, and 
infectious diseases. However, cancer related mortality has slightly increased 
since 1980 [25;26]. Despite a better understanding of the disease and the 
advent of modern technology and rationally targeted drugs, the incidence and 
cure rate of cancer have not improved (Table 1). This failure to control cancer 
deaths from common epithelial malignancies provides the ultimate rationale for 
an approach based on prevention, before the complex series of genetic and 
epigenetic events that result in invasive and metastatic malignancy have 
occurred. It has been estimated that more than two-thirds of human cancers 
could be prevented through appropriate lifestyle modifications. Doll and Peto 
have reported that an average of 35% of human cancer mortality is attributable 
to diet [27], which has two rational explanations: (1) the presence of suspected 
carcinogens in the diet and (2) the absence in the diet of compounds 
possessing cancer preventing properties. 
Cancer chemoprevention, as first defined in 1976 by Sporn, is the use of 
natural, synthetic, or biologic chemical agents to reverse, suppress, or prevent 
carcinogenic progression [28]. Chemoprevention has been successfully  
 
Cause of death 
 1980   
            
   Death          % 
 2003    
            
   Death          % 
All causes 
Diseases of Heart 
Malignant neoplasms 
Cerebrovascular diseases 
Accidents  
Chronic lower respiratory diseases 
Influenza and pneumonia 
Diabetes mellitus 
Chronic liver disease and cirrhosis 
Atherosclerosis 
Suicide 
Alzheimer’s disease 
Nephritis, nephritic syndrome and nephrosis 
Septicemia 
1 989 841
761 085 
416 509 
170 225 
105 718 
56 050 
54 619 
34 851 
30 583 
29 449 
26 869
100.0
38.3 
20.9 
8.5 
5,3 
2.8 
2.7 
1.8 
1.5 
1.5 
1.4
2 448 288 
685 089 
556 902 
157 689 
109 277 
126 382 
65 163 
74 219 
 
 
 
63 457 
42 453 
34 069 
100.0
28.0
22.7
6.4
4.5
5.2
2.7
3.0
2.6
1.7
1.4
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Figure 2: Chemopreventive strategies 
 
 
achieved in numerous animal experiments over the past 25 years, and has 
been validated in several major clinical trials (for review see [29;30])  Based on 
these findings and following the indications of the National Cancer Institute 
(NCI), five classes of mainly chemically synthesized chemopreventive agents 
are considered of high priority: selective estrogen receptor modulators 
(SERMs), non-steroidal anti-inflammatory drugs (NSAIDs), calcium compounds, 
glucocorticoids and retinoids. In parallel, the NCI identified about 40 edible 
plants possessing potential chemopreventive compounds, globally known as 
phytochemicals [31]. These dietary agents are believed to block or reverse the 
premalignant stage (initiation, promotion and progression) of multistep 
carcinogenesis. In detail the cellular and molecular mechanisms affected by 
phytochemicals include carcinogen activation/detoxification by xenobiotic 
metabolizing enzymes; DNA repair, cell cycle progression, cell proliferation, 
differentiation and apoptosis, expression and functional activation of oncogenes 
or tumor-supressor genes, angiogenesis and metastasis and hormonal and 
growth-factor activity [32] (further chemopreventive strategies are reviewed in 
Figure 2). 
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To meet the requirements an effective and acceptable chemopreventive agent 
should have certain  properties [33;34]:  
• Little or no toxic effects in normal and healthy cells 
• High efficacy against multiple sites 
• Capability of oral consumption 
• Known mechanism of action 
• Low cost 
• History of use by the human population 
• Acceptance by human population   
 
1.2.1 Cell cycle regulation 
 
Cell division consists of two consecutive processes, mainly characterized by 
DNA replication and segregation of replicated chromosomes into two separate 
cells which is divided into two stages, namely mitosis (M), the process of 
nuclear division and interphase, the periode between two mitosis phases. The 
stages of mitosis consist of prophase, metaphase, anaphase and telophase 
while the interphase is subdivided in G1, S and G2 phases (reviewed in [35]) 
(Figure 3). Each phase is characterized by distinct cellular processes that are 
required for proper cell division and is regulated by the activation of cyclins, 
which bind to cyclin-dependent kinases (CDKs) to induce cell-cycle progression 
towards S phase and later to initiate mitosis [36]. Different cyclins are required 
at different phases of the cell cycle. For the progression from G1 to S the D type 
cyclins bind to CDK4 and to CDK6 to form an active kinase that phosphorylates 
retinoblastoma (Rb) protein. In a hypophosphorylated state, Rb inhibits growth 
by sequestering the E2F transcription factor. Hyperphosphorylation of Rb by 
cyclin D-CDK4/6 results in the release of E2F, which activates transcription of 
cyclins for later phase transition as well as proteins required for DNA synthesis 
[37]. Another G1 cyclin is cyclin E which  
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Figure 3: Phases of the cell cycle (adopted from MANUSCRIPT V) 
 
 
associates with CDK2 to regulate progression from G1 into S phase [38]. Cyclin  
A binds with CDK2 and this complex is required during S phase [39]. In late G2  
and early M, cyclin A complexes with CDK1 to promote entry into mitosis which 
is further regulated by cyclin B in complex with CDK1 [40]. CDK activity can be 
counteracted by cell cycle inhibitory proteins, called CDK inhibitors (CKI) which 
bind to CDK alone or to the CDK-cyclin complex. Two distinct families of CKI 
have been discovered, the INK4 family (p15 (INK4b), p16 (INK4a), p18 (INK4c) 
and p19 (INK4d)) and the Cip/Kip family (p21 (Waf1, Cip1), p27 (Cip2) and p57 
(Kip2)) [41]. In cancer, there are fundamental alterations in the genetic control 
of cell division, resulting in an unrestrained cell proliferation. This cell cycle 
dysregulation occurs through mutation of proteins important at different levels of 
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the cell cycle, like CDKs, cyclins, CDK-activating enzymes, CKI, CDK 
substrates, and checkpoint proteins [42]. Hence, the control of cell proliferation 
represents an important preventive stragety in multistep carcinogenesis. 
 
 
1.2.2 Induction of apoptosis 
 
 
Apoptosis or programmed cell death is defined as an active physiologic process 
of cellular self-destruction, with specific morphologic and biochemical changes 
in the nucleus and cytoplasm [43]. The signaling events leading to apoptosis 
can be divided into two distinct pathways, namely the intrinsic and extrinsic 
pathway (Figure 4). Engagement of the intrinsic pathway results in altered 
mitochondrial membrane permeability and the release of pro-apoptotic factors 
including cytochrome c, caspase-9 and second mitochondria-derived activator 
of caspases (Smac)/DIABLO into the cytosol. Cytochrom c binds to the 
cytosolic protein apoptotic protease activating factor-1 (APAF-1) and 
procaspase-9 to form the “apoptosome”, which leads to activation of caspase-9 
and subsequently caspase-3, resulting in apoptosis [44]. This pathway is 
primarily governed by proteins of the Bcl-2 family, which include anti- and pro-
apoptotic molecules able to differentially affect mitochondrial homeostasis and 
cytochrome c release [45]. Moreover, other proteins belonging to the inhibitor of 
apoptosis protein (IAP) family are able to block a common step downstream of 
mitochondrial cytochrome c release by inhibiting terminal effector caspase-3 
and caspase-7, and interfering with caspase-9 activity and processing [46]. A 
second caspase-independent pathway is characterized by the leakage of 
apoptosis-inducing factor (AIF) from mitochondria, resulting in direct chromatin 
condensation and DNA fragmentation [47]. The extrinsic pathway is 
characterized by ligand fixation to death receptors present on the cell surface. 
These death receptors are members of the TNF (tumor necrosis factor) receptor 
gene superfamily, which share similar, cysteine rich extracellular domains [48]. 
Ligation of death receptors results in recruitment of adapter  
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Figure 4: Apoptotic pathways (adopted from MANUSCRIPT V) 
 
 
molecules such as FADD (Fas-associated death domain), which in turn recruits 
procaspase-8 to form the death inducing signaling complex (DISC) [49]. DISC 
releases caspase-8, which activates caspase-3 [50].  
Apoptosis is the mechanism used by metazoans to regulate tissue homeostasis 
through the elimination of redundant or potentially deleterious cells. The 
disruption of this mechanism is observed in a variety of cancers. Therefore 
induction of apoptosis is arguably the most potent defense against cancer.  
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1.3  Phytochemicals 
 
Figure 5:  Dietary agents and their major biological active compounds 
 
 
Information has been accumulated indicating that diets rich in vegetables and 
fruits can reduce the risk of a number of cancers [51]. Phytochemicals (non-
nutrient components in the plant-based diet), such as carotenoids, antioxidative 
vitamins, phenolic compounds, terpenoids, steroids, indoles and fibers, have 
been considered responsible for risk reduction [52] (Dietary phytochemicals that 
most often appear to be protective against cancer are summarized in Figure 5). 
In this project we were focusing on the anti-carcinogenic properties of two 
different phytochemicals, namely the polyphenolic Resveratrol and the 
triterpenoid Ursolic acid which will be introduced in the following section.  
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1.3.1 Resveratrol 
 
 
Resveratrol, chemically known as 3,5,4’-trihydroxytransstilbene (molecular 
weight=228.2), is a naturally occuring polyphenolic compound, also classified as 
a phytoalexin, which are herbal antibiotics produced in response to 
environmental stress factors including injuries, UV irradiation or fungal invasion 
[53]. Resveratrol-containing foods include grapes [54;55], wine [56], and 
peanuts [57;58]. An important factor for resveratrol in wine is the fermentation
time in contact with grape skins 
because resveratrol is produced by 
the skin but not by the fruit flesh 
[59]. This explains the low 
concentrations in white wine 
because the grape skin is not 
fermented in the production 
process [56]. Resveratrol was first 
detected in the root extract of the 
weed Polygonum cuspidatum [60], 
which has been known in asian folk medicine under the name Ko-jo-kon and 
was traditionally used to treat liver, skin and circulatory diseases [61;62]. 
Resveratrol came to scientific attention as a possible explanation for the 
“French paradox” as it exhibits beneficial effects on the development of 
cardiovascular diseases [63]. It has been shown to inhibit platelet aggregation 
and eicosanoid synthesis [64], to interfere with arachidonate metabolism [65], to 
exert strong inhibitory effects on reactive oxygen species produced by human 
polymorphonuclear leukocytes [66], to be an antioxidant more powerful than 
vitamin E in preventing low-density lipoprotein (LDL) oxidation [67], and to exert 
vasorelaxing effects on endothelium-intact aorta rings of rats [68]. Further 
studies could show that resveratrol is an agonist for the estrogen receptor which 
may also be relevant to the reported cardiovascular benefits of drinking wine 
[69].  
Anti-carcinogenic properties of reveratrol were first reported by Jang et. al  
demonstrating chemopreventive effectiveness against all the three major steps 
of carcinogenesis i.e. initiation, promotion and progression [70].  Several signal 
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transduction pathways have been examined to explain these effects [71;72]. We 
and others provide several lines of evidence, that resveratrol mediates these 
anti-carcinogenic effects partly through the modulation of polyamine metabolism 
[73-76]. 
 
1.3.2 Ursolic acid 
 
Ursolic acid (3β-hydroxy-urs-12-
en-28-oic-acid, molecular 
weight=456.7), the isomer of 
Oleanolic acid, is a pentacyclic 
triterpenoid compound which 
exists widely in natural plants in 
the form of free acid or as 
aglycones for triterpenoid 
saponins [77;78].  Ursolic acid 
naturally occurs in a large number of berries, like cranberries and blueberries 
[79], in the waxlike coatings of apples and pears [80] and other plants. It was 
also identified as the major biological active incredient in a large number of 
plants which are used in traditional east asian folk medicine as drugs exhibiting 
hepatoprotective, antiinflammatory and anti-tumor effects (for review see [81]), 
for example in the leaves of the Bearberry (uva ursi, urs=bear), which is the 
eponym of ursolic acid. Additionally, chemopreventive effects could be 
demonstrated in several cancer models comprising inhibition of proliferation as 
well as induction of apoptosis [82-84].  
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1.4  Polyamines 
Figure 6: Polyamine metabolism 
Regulation of intracellular polyamine content in mammalian cells is mediated by 
different key enzymes: the biosynthetic ornithine decarboxylase (ODC) and S-
adenosylmethionine decarboxylase (SAMDC) and the catabolic 
spermidine/spermine acetyltransferase (SSAT) and FAD-dependent polyamine 
oxidase (PAO) (adapted from [85]) 
 
 
The polyamines spermidine, spermine as well as their precursor putrescine are 
ubiquitious polycationic metabolites in prokaryotic and eukaryotic cells which 
play an essential role in cell growth by stabilizing DNA structure [86], influencing 
membrane functions [87] and cell cycle regulating genes [88]. Increasing 
concentrations are generally associated with cell proliferation and cell 
transformations induced by growth factors, carcinogens, viruses and oncogenes 
[89]. Therefore intracellular polyamine pool size is controlled strictly by the 
combined action of de novo synthesis, catabolism, uptake and export of 
polyamines. This regulatory mechanism include reactions catalyzed by the 
biosynthetic enzymes ornithine decarboxylase (ODC) and S-
adenosylmethionine decarboxylase (SAMDC) and the catabolic 
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spermidine/spermine acetyltransferase (SSAT) and FAD-dependent polyamine 
oxidase (PAO) [85] (Figure 6).  An association of excess polyamine levels with 
cancer was first reported in the late 1960s, when Russel and Snyder reported 
high levels of ODC activity in several human cancers [90]. In colorectal cancer 
tissue polyamine contents are increased 3-4 fold over that found in the 
equivalent normal colonic tissue [91]. Based on these findings pharmacological 
or natural inhibitors of polyamine metabolism have been studied in vitro [75;92] 
and in vivo [93] as new potent therapeutic strategies in cancer treatment and 
prevention.  
 
1.4.1 Inhibition of polyamine biosynthesis 
 
The recognition that polyamines are required for cell growth and that their 
metabolic pathway is frequently dysregulated in cancers led to the development 
of inhibitors for each step of the polyamine biosynthetic pathway. 2-
difluoromethylornithine (DFMO), an enzyme-activated irreversible inhibitor, 
remains the prototypical inhibitor of ODC. DFMO initially competes with 
ornithine for binding to the active site of ODC and is then decarboxylated by 
ODC to create a highly reactive intermediate that in turn inhibits ODC activity.  
Even though triggering promising effects in vitro, DFMO has been less 
successful in cancer therapy, resulting in cytostatic rather than cytotoxic effects 
in vivo [94]. The limited success of DMFO has been attributed to three factors: 
(1) the tumour is able to obtain sufficient polyamines to sustain growth from the 
pool, since the diet, a major source of polyamines would provide a continuous 
exogenous supply; (2) intestinal bacteria may represent a potential limited 
source of polyamines; and (3) polyamines may be effectively reutilized following 
their release from dead cells, especially those of the gut. Consequently, it 
should not be surprising, that attaining the goal of reducing high polyamine 
levels in tissues during cancer development might require targeting more 
processes in the regulatory mechanism of polyamine metabolism. Studies in 
experimental models could already show that combinations of two drugs, 
specifically, combinations of DFMO and non-steroidal anti-inflammatory drugs 
(NSAIDs) were more effective than single-agent strategies [95;96]. One aspect 
of the rationale for combining ODC inhibitors and NSAIDs might be that 
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catabolic SSAT provides another transcriptional target for several NSAIDs 
[95;97].  
Flamigni et al. could demonstrate that ODC expression could be regulated in 
leukaemia cells through exogenous ceramide-analogs. Ceramides are key 
compounds in the metabolism of sphingolipids and are emerging as important 
second messengers for various cellular processes including cell cycle arrest, 
differentiation and apoptosis.  
 
1.4.2 Induction of polyamine catabolism 
 
ODC is not the only polyamine metabolic gene that is regulated by oncogenes 
and tumour-suppressor genes as both SSAT and PAO activities were found to 
be decreased in human solid tumors [98]. In human colon and other 
gastrointestinal cancers the expression of spermidine/spermine acetyltranferase 
(SSAT) was described to be negatively regulated by the K-ras oncogene, which 
is commonly mutated – and, as a result, aberrantly activated [99]. K-ras 
activates the kinase Raf and suppresses expression of SSAT by inhibition of 
PPARγ which normally binds to PPARγ response elements in the promoter of 
the SSAT gene [95]. Peroxisome proliferator-activated receptors are ligand-
inducible transcription factors belonging to the nuclear hormone receptor 
superfamily [100;101], which regulate transcription of target genes by 
heterodimerizing with the retinoid x receptor and binding to PPAR response 
elements [100;102]. PPARγ is expressed at high levels in colonic epithelial and 
colon cancer cells [103]. Girnun and Spiegelmann [104] hypothesize that 
PPARγ is exerting its effects early in the carcinogenic process by suppressing 
tumor formation. Activation of PPARγ therefore could function as an important 
molecular target of chemopreventive agents. 
It was the discovery that specific antitumor polyamine analogs highly induce 
SSAT activity in a cell type specific manner that led to an increased interest in 
polyamine catabolism as a drug target. This ability of SSAT induction was 
suggested to correlate with the reduction of intracellular polyamines followed by 
cell growth inhibition and apoptosis [105-107].  
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1.5  Aims 
 
Interest in the concept and practice of chemoprevention as an approach for the 
control of cancer has increased greatly in the past few years. Multiple natural 
agents have been shown to be effective for blocking carcinogenesis in certain 
human cancers and animal models. Using non-toxic chemical substances 
therefore is regarded as a promising alternative strategy to therapy for control of 
human cancer. The observed anti-carcinogenic effects may be due to blocking 
effects on the carcinogenesis stages of initiation, promotion, or progression. 
However, the precise underlying molecular mechanisms remain largely 
unknown. Thus, the aim of our study was to characterize chemopreventive 
effects of the two phytochemicals resveratrol and ursolic acid in a cell culture 
model of colorectal cancer.  
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2 RESULTS 
 
2.1  PPARγ as a molecular target of resveratrol-induced 
modulation of polyamine metabolism (MANUSCRIPT I) 
 
Based on our former findings that resveratrol induces cell growth inhibition of 
colon cancer cells via induction of catabolic SSAT, together with the 
identification of PPAR response elements in the promoter of the SSAT gene by 
Babbar et al., the aim of this work was to specify the underlying molecular 
mechanisms and to identify a possible role of transcription factor PPARγ. First, 
we determined the effects of resveratrol on cell proliferation and cell counts of 
the two colorectal cancer cell lines Caco-2 and HCT-116. Both cell lines were 
incubated with increasing concentrations of resveratrol [30-200 µmol/L] for 24, 
48 and 72h. After each time interval, both cell proliferation ELISA (BrdU) and 
crystal violet staining were done. In HCT-116 cells, a significant time- and dose-
dependent decrease in cell proliferation and cell counts could be measured. 
The same effects could be observed in Caco-2 cells, which is in accordance 
with our earlier studies [108]. Next, we tried to investigate the role of PPARγ in 
resveratrol-induced activation of SSAT. As no complete PPARγ antagonist have 
been described hitherto, we transfected a dominant-negative mutant receptor in 
Caco-2 cells to abolish PPARγ-mediated functions. In this mutant highly 
conserved hydrophobic and charged residues (Leu468 and Glu471) in helix 12 
of the ligand-binding domain were mutated to alanine. So, this mutant retains 
ligand and DNA binding, but exhibits markedly reduced transactivation due to 
impaired coactivator recruitment [109].  Resveratrol leads to a significant 
increase of SSAT activity (p<0.05 vs. control) in Caco-2-wild type cells after 24h 
of incubation, which is in agreement with our previous data [75]. In Caco-2 
empty vector cells, resveratrol also significantly increases SSAT-activity (p<0.05 
vs. control) whereas no effects could be observed when PPARγ-mediated 
functions are suppressed in Caco-2-dnPPARγ mutant cells. To investigate the 
effects of resveratrol on PPARγ ligand-dependent activity, we did a chimeric 
Gal4-PPARγ transactivation assay. Because the chimeric receptor contained 
only hinge region and ligand binding domain of the PPARγ, any effect of 
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resveratrol affecting kinase-sensitive AF1 domain was ruled out. After 
incubation with resveratrol, we could generate similar effects of PPARγ agonist 
pioglitazone on PPARγ activity (p<0.01). To show evidence of resveratrol ability 
to increase PPARγ activity, we measured, after resveratrol treatment, the 
expression of cytokeratin 20, which is described to be a specific target gene of 
PPARγ activity in colorectal cancer cells [110]. Incubation with resveratrol led to 
an ~40% increase of cytokeratin 20 expression at after 72h (p<0.001 vs. 
control). We further did Western blot analysis to determine possible effects of 
resveratrol on translational level. However, no significant changes in PPARγ 
protein expression could be detected (unpublished data). In a next step 
Western blot analysis was done to determine possible effects of resveratrol on 
the expression of PGC1α (PPARγ coactivator 1α) and sirtuin homologue SIRT1, 
which exhibits PPARγ-suppressive effects in white adipocyte tissue. Resveratrol 
led to a significant dose-dependent increase in both PGC1α (~60%, p<0.05) 
and SIRT1 (~140%, p<0.01) expression after 24h of incubation. 
There are several lines of evidence that resveratrol mediates its 
chemopreventive actions via modulation of mitogen-activated protein kinase 
(MAPK) pathways. To examine p38 MAPK-mediated actions, we used the 
specific inhibitor SB203580. This anti-inflammatory drug inhibits the catalytic 
activity of p38 MAPK by competitive binding in the ATP pocket [111]. Incubation 
with resveratrol augmented phosphorylated p38 in a time- and dose-dependent 
manner, both in Caco-2 and HCT-116 cells (~300% at 200 µmol/L after 16h; 
p<0.01), whereas p38 MAPK concentration remained unaffected. To 
characterize the role of p38 activation in resveratrol-mediated induction of 
SSAT, we pretreated Caco-2 and HCT-116 with p38 inhibitor SB203580 [10-20 
µmol/L] for 1 hour and then added resveratrol for another 24 hours. Both in 
Caco-2 and HCT-116 cells, coincubation with SB203580 significantly diminished 
resveratol-induced SSAT activation (p<0.05 vs. resveratrol in Caco-2; p<0.01 
vs. resveratrol in HCT-116). In summary, our data confirm our earlier studies 
showing that resveratrol-mediated gowth inhibition of colorectal cancer cells 
seem to involve SSAT-induced polyamine catabolism. Here, we further 
demonstrate that transcription factor PPARγ acts as a p38-dependent target in 
resveratrol-induced molecular mechanisms.  
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2.2  De novo ceramide biosynthesis is associated with 
resveratrol-induced inhibition of ornithine decarboxylase 
activity (MANUSCRIPT II) 
 
Apart from inducing polyamine catabolism, resveratrol was also shown to inhibit 
key enzymes involved in the biosynthetic pathway of polyamine metabolism. 
And again we were interested in the underlying molecular mechanisms leading 
to these effects. In detail, the aim of this work was to study the potential 
involvement of ceramide biosynthesis in resveratrol mediated inhibition of 
biosynthetic ODC activity in colorectal cancer cells. First of all we examined the 
effect of resveratrol [50-200 µmol/L] on the intracellular ceramide 
concentrations of Caco-2 cells using mass-spectometry. After 24h of incubation 
we could observe a significant dose-dependent up-regulation of C16-ceramide 
levels ~6.5-fold at 200 µmol/L (p<0.001). Since natural ceramides are not 
permeant to cell membranes, our study has been carried out by using short 
chain cell-permeable analogs to determine the role of ceramides in these signal 
transduction pathways. Caco-2 and HT-29-cells were incubated with increasing 
concentrations of N-acetylsphingosine (C2-ceramide) and N-
hexanoylsphingosine (C6-ceramide) [1-40 µmol/L] for 24-72h. After each time 
interval both cell proliferation ELISA (BrdU) and crystal violet staining were 
performed. Both in Caco-2- and HT-29-cells a significant time- and dose-
dependent decrease in cell proliferation and cell counts could be measured. 
Resveratrol on the one hand induces intracellular ceramide synthesis and on 
the other hand reduces the protein levels of the protooncogenes ODC and c-
myc, a transcription factor that directly regulates the expression of ODC [75]. To 
reveal a possible coherency, we first measured the effects of C2- and C6-
ceramides in Caco-2- and HT-29 cells on ODC activity after 24h of treatment 
which both caused a significant inhibition in a dose-dependent manner 
(p<0.001). We further did Western blot analysis to measure effects on the 
protein levels of ODC and c-myc after treatment with the C6-ceramide. And 
actually a dose-dependent decrease both in c-myc (p<0.001) and ODC (p<0.05) 
protein levels comparable to the resveratrol-induced effects [75] could be 
observed after 6h of incubation. Two major pathways may contribute to 
intracellular ceramide accumulation: namely the sphingomyelinase (SMase)-
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dependent catabolism of sphingomyelin, as well as the de novo synthesis 
catalyzed through serine palmitoyltransferase (SPT). Hence, we tested whether 
selective pharmacological inhibitors of these two key enzymes were able to 
prevent resveratrol-induced inhibition of ODC activity. While co-incubation with 
the SMase inhibitor manumycin [1 µmol/L] causes no changes in resveratrol 
action, blockade of de novo ceramide synthesis with the SPT-inhibitors L-
cycloserine [1 mmol/L] and myriocin [5 µmol/L] counteracted inhibitory effects of 
resveratrol on ODC-activity. To further verify the involvement of ceramide 
synthesis in resveratrol-mediated effects we treated Caco-2 cells with 
resveratrol alone and in combination mith L-cycloserine and measured the 
protein levels of c-myc and ODC after 24h of incubation. As already shown in 
earlier studies resveratrol leads to a significant decrease of both c-myc 
(p<0.001) and (p<0.001) protein levels, which could be significantly reduced 
(p<0.05), when ceramide de novo synthesis was suppressed. To determine 
whether the decrease in c-myc and ODC are the cause of decreased growth 
rate or a result, we performed an add-back experiment with exogenous 
polyamines. For this we treated Caco-2 cells with spermine [50 µmol/L], 
resveratrol and the combination of both and measured cell counts after 48h of 
incubation. As spermine was able to counteract resveratrol-actions significantly, 
we conclude that the observed reduction of cell counts after resveratrol-
treatment is due to a reduction of intracellular polyamine levels.  
As shown in MANUSCRIPT I the activation of transcription factor PPARγ plays a 
crucial role in resveratrol-induced activation of catabolic SSAT. So we wanted to 
determine whether this receptor is also involved in ODC inhibition. In 
accordance to MANUSCRIPT I, we now investigated the effects of resveratrol on 
ODC activity in Caco-2-wildtype cells compared to Caco-2-cells transfected with 
either the empty vector or a dominant-negative PPARγ mutant after 24h. But in 
contrast to SSAT activation PPARγ seems not to be essential for resveratrol-
induced ODC inhibition as no differences could be observed, when PPARγ 
mediated functions are suppressed. 
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2.3  Ursolic acid induces apoptosis through PPARγ mediated 
SSAT-activation in colon cancer cells (MANUSCRIPT III) 
 
In addition to polyphenols, triterpenoid compounds, e.g. ursolic acid, were also 
described to show potent chemopreventive and anticarcinogenic properties in 
malignant cell lines. Little is known about the underlying molecular mechanisms 
of ursolic acid related effects on cell proliferation and apoptosis in colorectal 
cancers. Thus the major aim of this study was to analyze modulatory effects on 
cell cycle regulating proteins as well as pro- and anti-apoptotic factors and to 
further characterize signal transduction pathways leading to these 
chemopreventive actions.  
Caco-2-, HCT-116- and HT29-cells were incubated with increasing 
concentrations of ursolic acid [5-30 µmol/L] for 24 h, 48 h and 72 h. After each 
time interval both cell proliferation ELISA (BrdU) and crystal violet staining were 
performed. While not effective in Caco-2 cells after 24h of incubation ursolic 
acid leads to significant time- and dose-dependent decrease in cell counts 
(p<0.001) as well as to a significant inhibition of cell proliferation (p<0.001) in all 
cell lines after 48h at the latest. To decipher the molecular mechanisms leading 
to cell growth inhibition we started to measure the expression status of several 
cell cycle regulating proteins, whereby the most prominent effects could be 
observed with the cell cycle inhibitors p21WAF1/Cip1 and p27Kip1. While ursolic acid 
leads to a significant dose-dependent increase of p21WAF1/Cip1 protein levels 
already after 24h of incubation (~ 30%, p<0.05), an increase of p27Kip1 levels 
could not be observed until 48h of treatment (~ 40%, p<0.05). Another 
interesting change could be detected in the expression levels of cyclin E, which 
is essential for progression through the G1-phase of the cell cycle and for 
initiation of DNA replication by interacting with and activating its catalytic 
partner, the CDK 2 and therefore can be considered as a promotor of cell 
replication and proliferation. In contrast to our expectations, we could observe a 
significant dose-dependend increase in the protein levels of  cyclin E in Caco-2 
cells after 24h of incubation with ursolic acid (~ 40%, p<0,05). 
To evaluate a possible influence of apoptosis induction on the cell growth 
inhibition of Caco-2, HCT-116 and HT-29 cells, we investigated DNA 
fragmentation as a marker of programmed cell death. Thereby, ursolic acid 
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causes a significant dose-dependent increase of DNA-fragments after 24h of 
incubation [p<0,001 vs. control in all cell lines]. Additionally, we measured 
caspase-3-activity in Caco-2 cells at the same point of time as a further marker 
of apoptotic actions. Again, ursolic acid seems to exhibit pro-apoptotic 
properties, as we could also observe a significant dose-dependent increase of 
caspase-3-activity in Caco-2-cells [p<0.001 vs. control]. To specify the 
underlying molecular mechanisms leading to apoptosis after incubation with 
ursolic acid, we examined several apoptosis regulating proteins in Caco-2 cells 
by Western blot analysis. To analyse the effects on the intrinsic pathway we 
have chosen members of the Bcl-2 family of proteins, which are known to 
regulate membrane permeability and cytochrome c release from mitochondria. 
While ursolic acid leads to an upregulation of proapoptotic BAX protein levels 
(up to ~20%), the expression of the antiapoptotic Bcl-2 was diminished after 
24h of incubation (about ~40%). These single effects result in a significant 
increase of the BAX/Bcl-2 protein ratio up to 60% (p<0.001), which is generally 
known to trigger apoptosis. We further measured protein levels of TRAIL (TNF-
related apoptosis-inducing ligand) an immunological inducer of extrinsic 
mechanisms leading to programmed cell death. This ligand, binding to specific 
death receptors on the cell surface, was also significantly upregulated after 24h 
of incubation with ursolic acid in a dose-dependent manner (p<0.05). As 
resveratrol was shown to mediate its chemopreventive effects at least partly 
through the modulation of polyamine metabolism (MANUSCRIPT I + II), we were 
interested if ursolic acid modulates similar intracellular mechanisms. Hence, we 
examined the effects of ursolic acid on ODC and SSAT activity in Caco-2-
wildtype cells compared to Caco-2-cells transfected with either an empty vector 
or a dominant negative PPARγ mutant to investigate effects mediated by 
PPARγ. In contrast to resveratrol, ursolic acid only leads to a significant 
increase of SSAT activity (p<0,001 vs. control) in Caco-2-wildtype cells after 24 
h of incubation but does not simultaneously inhibit ODC activity (unpublished 
data). In Caco-2-empty vector cells ursolic acid also significantly increases 
SSAT-activity (p<0,001 vs. control), whereas no effects could be observed 
when PPARγ mediated functions are suppressed in Caco-2-dnPPARγ mutant 
cells. 
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3 DISCUSSION 
 
3.1  Resveratrol-induced modulation of polyamine metabolism 
 
The phytoalexin resveratrol (3,4’,5-trihydroxystilbene) exhibits multiple 
chemopreventive effects comprising cell growth inhibition [108;112], induction of 
apoptosis [113], and prevention of angiogenesis [114], whereby the underlying 
molecular mechanisms are only partly understood (MANUSCRIPT IV + 
MANUSCRIPT V). One of our theories is concerned with the role of polyamines or 
polyamine metabolism respectively. Intracellular polyamine levels are 
maintained within very narrow limits because decreases of polyamine 
concentrations interfere with cell growth, whereas an excess seems to be toxic 
[115]. The three key enzymes of polyamine metabolism are ODD and SAMDC, 
the rate-limiting enzymes of polyamine biosynthesis, and SSAT, which controls 
polyamine catabolism [116]. Wolter et al. showed that resveratrol-induced 
growth arrest of Caco-2 cells is accompanied by inhibition of polyamine 
biosynthesis as well as activation of polyamine catabolism [75]. One aim of our 
work was to further characterize molecular events leading to the observed 
modulation of polyamine metabolism. 
 
3.1.1 Mitogen-activated protein kinases 
 
Cells recognize and respond to extracellular stimuli by engaging specific 
intracellular programs, such as the signalling cascade, that leads to activation of 
the mitogen-activated protein kinases (MAPKs). All eukaryotic cells possess 
multiple MAPK pathways, which coordinately regulate diverse intracellular 
activities comprising gene expression, mitosis, survival and apoptosis, and 
differentiation. MAPKs are generally expressed in all cell types, yet their 
functions to regulate specific responses differ from cell type to cell type. To 
date, five distinct groups of MAPKs have been characterized in mammals: 
Extracellular signal-regulated kinase (ERK) 1/2, the p38 kinase (p38α, β, γ and 
δ), c-Jun N-terminal kinase (JNK) 1, 2, 3 and ERK3, ERK4, ERK5, which follow 
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the same principle of phosphorylation and activation cascades (Reviewed in 
[117]). Given the role of MAPKs in many critical responses reqired for cellular 
homeostasis, it is not surprising, that loss of fine control of MAPK regulation 
resulting from mutation or changes in expression of proteins regulating MAPK 
signalling contribute to cancer and thus the modulation of MAPK pathways 
presents an important anti-cancer strategy [118]. MAPK p38 for example has 
recently gained attention as a tumor suppressor, as it, upon activation, induced 
terminal differentiation in rhabdomyosarcoma cells [119]. Similarly, deletion of a 
p38-inhibitory phosphatase blocked Hras1- and erbB2-induced carcinogenesis 
in vivo, whereas inhibition of p38 promoted tumor formation [120]. Other studies 
have evaluated p38 activity in response to chemotherapy, as diverse 
chemotherapeutic agents stimulate apoptosis in a p38-dependent manner 
[121;122].  
In several studies, resveratrol was also shown to mediate multiple functions by 
modulating MAPK pathways (Reviewed in MANUSCRIPT V and [52]). In 
MANUSCRIPT III we could show as well that incubation with resveratrol causes 
phosphorylation, and thus activation, of p38 MAPK in colon cancer cells. 
Furthermore, combination of resveratrol with an inhibitor of p38 MAPK leads to 
an inhibition of resveratrol-induced SSAT activation both in Caco-2 and HCT-
116 cells. Consequently, an activation of MAPK cascade by resveratrol can be 
assumed in our system. But, while the activation of p38 plays a crucial role in 
resveratrol-induced SSAT-activation, an involvement in ceramide-mediated 
actions, and thus inhibition of ODC-activity (MANUSCRIPT II), is discussed 
controversially [123-125] and requires further investigations. 
 
3.1.2 Peroxisome-proliferator activated receptor γ 
 
The PPARγ is a nuclear receptor that controls the expression of a large array of 
genes involved in adipocyte differentiation [126], lipid metabolism [127], insulin 
sensitivity [128], inflammation [129] and artherogenesis [130]. There is much 
evidence that PPARγ plays another crucial role in carcinogenesis as it was 
shown to affect cell growth, differentiation and apoptosis in several malignant 
cell lines [131-133]. Additionally, an association between loss-of-function 
mutations of PPARγ with the development of colorectal cancer in humans was 
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documented [134]. According to the current findings, an essential role for 
PPARγ in enhancing SSAT enzyme activity is assumed [95]. In fact, we could 
show that, in contrast to Caco-2-wild type and Caco-2-empty vector cells, 
resveratrol failed to increase SSAT activity in Caco-2-dnPPARγ cells. 
Here our results point out another important role of PPARγ in resveratrol-
mediated actions whereas resveratrol-dependent PPARγ activation seem to be 
mediated at least partly by an activation of the ligand binding domain (LBD/ 
AF2) because a Gal4-PPARγ chimeric receptor was activated by resveratrol at 
a concentration of 100 µmol/L, and this concentration was sufficient to induce 
SSAT as well. In addition, our results suggest that activation of PPARγ by 
resveratrol is due to kinase activation, leading to phosphorylation-dependent 
activation of PPARγ coactivators like PGC-1α [135]. Coactivators all interact 
with a similar surface of the activated ligand binding domain of the receptors 
and have been suggested to mediate their transcriptional activity [136]. It is well 
established that, in addition to transcription factors, coactivators can also be 
targets of multiple signal transduction pathways in response to different stimuli 
[137]. Puigserver et al. [138] could show that PGC-1α is activated through p38 
MAPK. The mechanism by which p38 activates PGC-1α is not yet clear, but it is 
suggested that p38 MAPK–mediated phosphorylation counteracts repressor 
effects, possibly by encouraging the release of a repressor from PGC-1α [139]. 
Upon activation, PGC-1α docks on PPARγ and thus can modulate its 
transcriptional activity [140]. In addition to PGC-1α, resveratrol further leads to 
an activation of SIRT1, a member of the silent information regulator 2 (Sir2) 
families of proteins (sirtuins; ref. [141]). SIRT1 is mainly linked to negative 
regulation of gene expression as a cofactor through protein deacetylation [142]. 
However, there is evidence that SIRT1 can act positively and negatively to 
control gene expression as a cofactor for PGC-1α. These opposite effects could 
possibly be due to the recruitment of a different set of coactivators and 
corepressors through PGC-1α/SIRT1 [143]. This could further be an explanation 
for the repressive effects of SIRT1 on PPARγ in white fat where PGC-1α is very 
low [144].  
We were further interested, whether PPARγ plays another crucial role in 
resveratrol-induced ODC inhibition. But here, in contrast to SSAT induction, 
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PPARγ activation seems not to play a critical role as no differences could be 
observed when PPARγ mediated functions are suppressed. 
 
3.1.3 Sphingolipid metabolism 
 
Until the late 1970s lipids were primarily thought to serve as inert structural 
components of cellular membranes, but in recent years it has become more 
evident that lipids also act as signalling molecules to regulate fundamental 
cellular responses, such as cell death and differentiation, proliferation and 
certain types of inflammation [145-147]. One important class of membrane lipids 
acting as signaling molecules are the sphingolipids, which include ceramides 
and sphingosine. The generation of ceramide is either triggered by the action of 
sphingomyelinases, which hydrolyze the plasma membrane component 
sphingomyelin to yield ceramide and phosphorylcholine, or by de novo 
synthesis which is initiated by condensation of serine and palmitoyl-CoA 
catalyzed by SPT [148]. Various biological responses have been attributed to 
ceramide including cell growth inhibition and induction of apoptosis [149-151]. 
Furthermore, several chemotherapeutic agents have been shown to act, at least 
in part, by increasing tumor cell ceramide via de novo synthesis [152]. 
Ceramide can be metabolized by glycosylation, acetylation, or by catabolism to 
sphingosine, which can then be phosphorylated to the anti-apoptotic 
sphingosine-1-phosphate. Particularly the cellular balance between ceramide 
and sphingosine-1-phosphate seems to be crucial for a cell’s decision to either 
undergo apoptosis or proliferate, two events which are implicated in tumor 
development and growth [153]. Thus, pharmacological manipulation of 
sphingolipid metabolism to enhance tumor cell ceramide offers a novel 
approach to cancer chemoprevention and therapy.  
Interestingly, we could shown, that the antiproliferative effects of resveratrol 
closely correlate with a dramatic increase of endogenous ceramide levels. 
Similar effects could be observed in a metastatic breast cancer cell model, 
when ceramide levels increased ~5- and 10-fold after treatment with resveratrol  
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Figure 7: Ceramide metabolism 
Major synthetic and metabolic pathways for ceramide. Ceramide can be 
produced via a de novo biosynthetic pathway which is initiated by condensation 
of serine and palmitoyl-CoA catalyzed by serine palmitoyltransferase as well as 
by sphingomyelinase-mediated hydrolysis of sphingomyelin (Adapted from 
[154]). 
 
 
32 and 64 µmol/L, respectively, in comparison with untreated cells [155]. To 
further examine the cellular activities of ceramide, we worked with the 
exogenous cell-permeant ceramide-analogs N-acetylsphingosine (C2-
Ceramide) and N-hexanoylsphingosine (C6-Ceramide). And actually, treatment 
with C2- or C6-ceramide caused distinct growth inhibition in our colorectal 
cancer cell model which seems to be the mechanistic explanation for observed 
growth inhibitory effects of resveratrol.  
Nearly 70% of human cancers are associated with the activation of proto-
oncogene c-myc [156], a transcription factor that directly regulates the 
expression of ODC by binding to specific CAGGTG sequence in the gene 
promoter [157] Based on our earlier findings that resveratrol regulates the 
expression of both c-myc and ODC genes [75], together with the results from 
Flamigni et al. [155] who demonstrated a reduction of c-myc and ODC 
expression in leukemia cells after ceramide-treatment, we tried to identify a 
possible involvement of ceramide synthesis in the regulatory pathway in 
colorectal cancer cells. We measured c-myc as well as ODC expression and 
DISCUSSION  
26 
activity after treatment with C6-ceramide and with resveratrol in combination 
with the specific serine palmitoyltransferase inhibitors L-cycloserine and 
myriocin. While C6-ceramide led to an obvious decrease of both c-myc and 
ODC protein levels, L-cycloserine and myriocin but not sphingomyelinase-
inhibitor manumycin conspicuously counteracted the inhibitory effects of 
resveratrol. These data suggest that the induction of ceramide de novo 
biosynthesis but not hydrolysis of sphingomyelin is involved in resveratrol-
mediated inhibition of ODC.  
 
3.1.4 Summary and conclusion 
 
In summary, our data confirm our earlier studies showing that resveratrol-
mediated growth inhibition of colorectal cancer cells seems to involve 
modulation of polyamine metabolism. Here we further show that transcription 
factor PPARγ acts as a p38-dependent target in resveratrol-induced activation 
of polyamine catabolism (MANUSCRIPT I). On the other hand we could 
demonstrate that the induction of de novo ceramide biosynthesis plays a crucial 
role in the inhibition of polyamine biosynthesis (MANUSCRIPT II) (For summary 
see Figure 8). Besides a decrease in cell proliferation, the observed reduction 
of cell growth is probably due to an induction of apoptosis, as Wolter et al. [108] 
showed an obvious increase of caspase-3-activity in resveratrol-treated cells. 
Recent studies further indicate that the activation of catabolic SSAT is related to 
an induction of programmed cell death [105]. These aspects of resveratrol-
action require further investigations.  
The identification of increased polyamine concentrations in a variety of cancer 
tissues has led to the design and development of inhibitors of polyamine 
metabolism as a new strategy for therapeutic or preventative interventions. The 
best-known inhibitor of polyamine biosynthesis is α-difluoromethylornithine 
(DFMO), a specific inhibitor of ornithine decarboxylase (See introduction). The 
failure of ODC monotherapy in vivo may at least partly also be due to inhibitory 
effects on catabolic SSAT activity, as DFMO effectively prevented SSAT- 
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Figure 8: Possible Mechanisms of Resveratrol action 
  Further details are described in text 
 
 
induced growth inhibition in a prostate cancer model while typically inhibiting cell 
growth rather than preventing cell growth inhibition [158]. Although much 
emphasis in the past has been on the biosynthetic pathway of polyamine 
metabolism, considerable interest has recently been generated with regard to 
the catabolic pathways, maintaining a properly balanced ratio of polyamines in 
cells. This suggestion may well explain the increased efficacy of combined 
chemopreventive therapy with non-steroidal anti-inflammatory drugs (NSAIDS) 
in animal models, as these agents recently have been shown, among others, to 
induce SSAT gene expression [92]. In this context resveratrol could show great 
potential in the chemoprevention and therapy of colorectal cancers, by 
simultaneously leading to SSAT activation as well as ODC inhibition. 
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3.2  Molecular characterization of the chemopreventive 
activities of pentacylic triterpene ursolic acid 
 
Ursolic acid is a pentacyclic triterpenoid, with anti-cancer and anti-inflammatory 
properties. Attempts to show favourable effects in vitro have led to the 
identification of multiple direct targets for this compound. Inhibition of cell cycle 
progression in the G1 phase for example was known to be associated with a 
marked decrease in the protein expression of cyclins and their activating 
partners the cyclin-dependent kinases and with a concomintant induction of cell 
cycle inhibitors in miscellaneous cancer cell lines [83;84]. Unfortunately, little 
research is done in colon cancer cells thereby mainly focusing apoptotic 
mechanisms.  
 
3.2.1 Cell cycle regulation 
 
Each phase of the cell cycle is governed by a wide spectrum of protein families. 
Many of these proteins are synthesized and activated in a precise phase of the 
cell cycle. In the past decade, the critical role that cell cycle regulation plays in 
cancer development has been clearly established [159-161]. Indeed, the list of 
cell cycle perturbations involved in tumor progression has dramatically 
increased in the last years [159;162] and unscheduled cell proliferation has 
become one of the chief causes described for malignancy and carcinogenesis 
[163].  
After detecting potent cell growth inhibitory properties of ursolic acid we started 
to measure the expression status of several cell cycle regulating proteins, 
whereby the most prominent effects could be observed in the upregulation of 
cell cycle inhibitors p21WAF1/Cip1 and p27Kip1. The observed induction of 
21WAF1/Cip1 is in accordance with results found in other malignant cell lines which 
could show the same effects ursolic acid [83;84;164], but we are the first to 
describe regulatory effects on p27Kip1. Contrary to expectations incubation with 
ursolic acid also leads to a conspicuous increase of cell cycle progressor cyclin 
E, which is however consistent with earlier findings by Wolter et al. [108] and 
Schneider et al. [73], which could show the same effects after treatment with the 
polyphenol resveratrol and take this as a result of a cell cycle arrest in the S-
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phase. However, cell cycle analysis of ursolic acid treated cells presents a 
predominant arrest in the G1 phase [83;165]. These controversial results will 
deserve further investigations. Moreover, there are several lines of evidence, 
that the induction of cyclin E by genotoxic stress, such as ionizing radiation 
[166] or chemotherapeutic agents [167] could play a functional role in the 
initiation phase of apoptosis in malignant cell lines, in addition to its reported 
key regulatory role on the control of the G1 to S-phase transition and the 
initiation of DNA replication [168]. It has recently become evident, that cyclin E 
can be processed proteolytically, with the resulting fragments playing important 
biological and pathological roles. In cyclin E-overexpressing tumor-derived cell 
lines, cyclin E is proteolytically cleaved to generate N-terminally truncated low 
molecular weight forms that are more resistant to the CKI p21WAF1/Cip1 and 
p27Kip1. Furthermore, cleavage of cyclin E results in loss of its CdK2 associated 
kinase activity, and consequently its cell cycle function. These low molecular 
weight forms in turn might exhibit more apoptosis-inducing properties [169]. 
Another interesting observation is the simultaneous accumulation in both p27Kip1 
and cyclin E levels, which normally correlate negatively as there exist 
interdependence regulatory mechanisms. These simultaneous events are 
known to be characteristic phenotypes in cells derived from mice lacking S-
phase kinase associated protein 2 (Skp2) [170] suggesting a possible 
involvement of protooncogene Skp2 in the regulation of p27Kip1 and cyclin E, 
which might provide another target of ursolic acid mediated actions.  
 
3.2.2 Induction of apoptosis 
 
Apoptosis, a form of programmed cell death, plays a fundamental role in the 
maintenance of tissues and organ systems by providing a controlled cell 
deletion to balanced cell proliferation. It is now apparent that many dietary 
chemopreventive agents with promise to human consumption can also 
preferentially inhibit tumor cell growth by targeting one or more signalling 
intermediates leading to induction of apoptosis. Two major apoptosis pathways 
have been identified, the death receptor or extrinsic pathway and the 
mitochondrial or intrinsic pathway. The mitochondrial pathway is regulated by 
members of the bcl-2 protein family, which can be divided in pro- and anti-
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apoptotic groups [171]. Because the activation of mitochondria has been 
considered as the “point of no return” in the apoptotic process, the manipulation 
of mitochondrial activation with proapoptotic intentions has been envisaged as a 
potential therapeutic target. While ursolic acid leads to an upregulation of 
proapoptotic BAX protein levels, the expression of the antiapoptotic Bcl-2 was 
diminished after 24h of incubation. This results in a significant increase of the 
BAX/Bcl-2 protein ratio which is generally known to trigger apoptosis [172;173]. 
The extrinsic pathway of apoptosis is activated at the cell-surface when a 
specific ligand binds to its corresponding death receptor. Death receptors, like 
tumor necrosis factor (TNF) receptor, TRAIL receptor and Fas belong to the 
TNF receptor superfamily which consists of more than 20 proteins with a broad 
range of biological functions [174]. The TRAIL ligand and its receptors are of 
special interest for cancer therapy, since TRAIL has been shown to 
predominantly kill cancer cells, while sparing most other cells [175]. In certain 
tumor cell lines, TRAIL protein expression could be induced by 
chemopreventive agents resulting in TRAIL-mediated apoptosis in an autocrine 
or paracrine manner [176-178]. This suggests that endogenously expressed 
TRAIL, which we could also observe in our cells after ursolic acid treatment, 
may be at least partly responsible for the observed chemopreventive effects. 
Taken together ursolic acid seems to lead to activation both of extrinsic and 
intrinsic signaling pathways both resulting in caspase-3 activation, followed by 
DNA fragmentation and programmed cell death.  
 
3.2.3 Modulation of polyamine metabolism 
 
Based on the findings in Manuscript I and II we were interested whether the 
modulatory effects on the polyamine metabolism are specific for polyphenolic 
resveratrol or if reduction of intracellular polyamines is a common 
chemopreventive strategy used also by other phytochemicals like triterpene 
ursolic acid. A correlation between polyamines and cancer have been 
extensively studied for decades, pointing out the inhibition of polyamine 
biosynthetic enzymes ODC and SAMDC or activation of catabolic enzyme 
SSAT as a potential chemopreventive strategy [179;180]. An association 
between SSAT induction followed by catabolism of the ubiquitous intracellular 
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polyamines and subsequent apoptotic responses was first reported by Ha et al 
[105]. Furthermore, Chen et al. [181] could demonstrate that selective 
interference of polyamine-analogue induced SSAT prevents apoptotic signaling 
and apoptosis in human melanoma cells. Much on the focus on SSAT has been 
on the functional level, but the regulation of SSAT gene expression has also 
been a subject of recent investigations. As already mentioned, the transcription 
factor PPARγ was shown to be involved in this regulatory mechanisms [95] 
[MANUSCRIPT I]. We could show that also ursolic acid seems to activate SSAT in 
a PPARγ-dependent manner. But unlike resveratrol [MANUSCRIPT I], ursolic acid 
could not simultaneously inhibit the activity of biosynthetic ODC (unpublished 
data).  
 
3.2.4 Summary and conclusion 
 
Summarizing our results, the observed reduction of cell growth of colon cancer 
cell lines after treatment with ursolic acid presumably results from a large 
increase in the number of apoptotic cells. The modulation of the polyamine 
metabolism, especially the induction of the catabolic SSAT via PPARγ-
dependent mechanisms thereby seems to present the major molecular target in 
the induction of programmed cell death.  
Hence, providing potent chemopreventive activities in vitro, ursolic acid could in 
theory possibly serve as alternatives to chemically designed antineoplastic 
agents, as constituents of therapeutic drug combinations in advanced disease, 
or as adjuvant treatments.  
 
 
3.3  Bioavailability of Phytochemicals 
 
The bioavailability of a nutrient is defined by its degree to which it becomes 
available to the target tissue after administration. One important cause of failure 
in cancer therapies it due to a defect of drug accumulation in cancer cells. 
Indeed, the action of chemopreventive or chemotherapeutic agents can be 
nullified by a failure of their absorption, distribution, metabolism or an increase 
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in their excretion. Hence, the knowledge of absorption and metabolism of a 
compound in vivo is the precondition to determine its bioavailability.  
The absorption and transport of resveratrol have been studied in several 
models: isolated rat intestine [182;183], rats and mice after oral administration 
[184-188], human colon carcinoma Caco-2 cell line [189], hepatocytes [190] and 
healthy human subjects [187;191;192].  
These experiments showed, that jejunum and, to lesser extend, illeum are 
involved in the absorption of resveratrol. Using radiolabelled resveratrol 
administered orally, an appreciable fraction, 50-70% of the dose, was absorbed 
in rats [187], and radioactivity could be recovered from the stomach, liver, 
kidney, intestine, bile and urine in mice [188]. Intragastric administration of 
2mg/kg, 20mg/kg and 50mg/kg resveratrol to rats generated peak values of 
2µM, 1.2µM and 6.6µM in plasma. After oral administration to humans 
(25mg/70kg) the amount of free resveratrol in plasma and serum reached 
~37nM (less than 2% of total resveratrol) [192]. The appearance of a new 
resveratrol peak 6h after consumption suggests enteric recirculation of 
conjugated metabolites by reabsorption after intestinal hydrolysis [193]. 
In contrast, most mechanistic studies in vitro suggest that carcinogenesis-
modulating effects of resveratrol require the sustained presence of 5-100µM, 
which, according to the mentioned studies, seems hardly to be realizable in 
vivo. 
Pharmacokinetic studies in mice and rats suggest consistently that resveratrol is 
well absorbed and rapidly glucuronidated and sulphated both in the liver and 
intestinal epithelial cells [183;187;188;194]. In humans, following its absorption, 
resveratrol is rapidly metabolized in the liver by phase-2 drug-metabolizing 
enzymes to water-soluble trans-resveratrol-3-o-glucuronide and trans-
resveratrol-3-o-sulfate, accounting for its predominant urine excretion. 
Compared to resveratrol, which has a plasma half-life of 8-14min, these 
metabolites have a plasma half-life of about 9.2h [192]. Although modifications 
such as glucuronidation and sulphation typically reduce the cell permeability of 
drugs and aid in their excretion, the undeniable in vivo efficiacy of resveratrol 
(see next chapter), despite its low bioavailability, has led to the speculation that 
its metabolites could retain some activity. Research into the actions of 
metabolites has been hampered by the lack of commercial sources, but should 
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proceed more readily now that synthetic molecules have been established by 
several groups [192;193;195]. 
Most bioavailability studies on resveratrol concentrate on absorption rates and 
plasma levels, but in the case of colorectal cancers, it might also be interesting, 
which amount of resveratrol is not absorbed and reaches the colon. 
Unfortunately, there is a lack of data measuring fecal concentrations after 
resveratrol consumption. To our knowledge solely Walle et. al examined fecal 
recovery of [14C]-Resveratrol after oral (25mg) and i.v. (0.2mg) doses in six 
volunteers which was highly variable (0.3-38%) [192]. Unfortunately, the 
number of participants in this study was very small, which is particularly critical 
due to the interindividual variability in xenobiotic metabolisms. The relevance of 
fecal concentrations becomes apparent in a recent study, when Karlsson et al. 
could show that fecal water from volunteers consuming a vegetarian diet 
potently reduced COX-2 protein levels and PGE2 production in colorectal cancer 
cells [196]. This is in line with earlier publications demonstrating that dietary 
alterations can influence the biochemical composition of fecal water [197;198]. 
Hence, intraluminal accumulation of resveratrol might be another hypothesis to 
explain the discrepancy between low bioavailability and effectiveness in vivo 
which requires further investigations.    
While the bioavailability of resveratrol is comparatively well characterized by 
now, little work was done on pharmacokinetic studies of ursolic acid. In one 
study plasma samples taken from rats that had received Lu-Ying extract, whose 
major effective constituent is ursolic acid, orally were analysed using a rapid 
and sensitive LC-MS method. These measurements demonstrated that ursolic 
acid exhibits a high binding activity in organs and a low blood distribution. This 
low bioavailability was due to a poor absorption rate and to rapid metabolization 
in entero- and hepatocytes [199].  But even though these results doubt the 
effectiveness of ursolic acid in vivo, a very recent study, examining the effect of 
orally administered ursolic acid on the formation of aberrant crypt foci (ACF) 
and intestinal SMase activity in azoxymethane (AOM)-treated rats, indicates 
that ursolic acid provides chemopreventive effects in the initiation phase of 
colon cancer associated with changes in SM metabolism, as the incidence of 
ACF could be significantly reduced after ursolic acid consumption when 
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compared to control animals [200]. These auspicious results raise hope for a 
clinical relevance of ursolic acid in therapeutic approaches of the future. 
 
3.4  Red wine consumption as a chemopreventive strategy? 
 
As red wine is the main dietary source of resveratrol in the western diet, one 
frequently asked question is: “So, how much of red wine do I have to drink 
then”? The concentrations of trans-resveratrol in red wine vary widely, but a 
reasonable estimate is about 5mg/L [201;202]. Assuming a consistent daily 
intake of 375ml, or about two glasses red wine, a person weighing 70kg would 
receive a dose of ~27µg/kg body weight each day. At higher doses, the 
detrimental effects of alcohol are likely to mask any health benefits. Consuming 
more than four drinks per day, for example, nullifies the beneficial effect of 
alcohol on the risk of myocardial infarction [203] and increases the development 
of alcoholic liver diseases [204]. Vitaglione et al. recently studied the 
bioavailability of trans-resveratrol after red wine consumption [195]. Resveratrol, 
its 3-glucuronide and its 4’-glucuronide were all detected sporadically in the 
plasma. This low recovery, due to a rapid metabolization and clearance of the 
compound, raises doubts about a possible association between the established 
beneficial health effects of moderate red wine consumption and the presence of 
resveratrol. But it is worth considering the potential interactions of resveratrol 
with other dietary constituents. Resveratrol synergistically induced apoptosis in 
leukaemia cells with both quercetin and ellagic acid [205], inhibited iNOS 
expression with ethanol [206], and prevented lipid peroxidation with tocopherol 
[207]. These results might help to explain how relatively low doses of resveratrol 
obtained from red wine or other dietary sources could produce a measurable 
health benefit. Thus, the protective effects associated with a moderate 
consumption of wine (e.g. the famous French paradox) could rather be due to 
the whole composition of compounds contained in wine and not to resveratrol 
alone, or to reasons different than wine consumption, such as a healthy lifestyle 
based on a correct dietary regime, practice of sports, and no smoking habit.  
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3.5  Therapeutic indications for Resveratrol in colorectal 
cancers – Future perspectives 
 
Table 2 Resveratrol in Preclinical animal models 
Modela Daily Doseb Route Efficacyc Plasma 
levels [µM] 
Ref. 
 
NMU-induced breast cancer in rat 
 
AOM-induced colon cancer in rat 
DMBA-induced breast cancer in rat 
NMBA-induced oesophageal cancer in rat 
APCMin+/+ mouse  
 
100 mg/kg 
10 mg/kg 
200 µg/kg 
1 mg/kg 
1 or 2 mg/kg 
15 mg/kg 
 
Igd 
Ig 
Water 
Diet 
i.g. or i.p. 
Water 
 
+ 
- 
+ 
+ 
+ 
+ 
 
~14 
~1-2 
~0.02 
~0.1 
~0.1-1 
~1-2 
 
[208] 
 
[209] 
[210] 
[211] 
[212] 
Dose, chemopreventive efficacy, and putative peak plasma levels of resveratrol in preclinical 
animal models in vivo (adapted from [201]) 
a NMU, AOM, azoxymethane; DMBA, 7,12-dimethylbenzanthracene, NMBA, ;  
b Doses of resveratrol admixed to the diet or drinking water are approximate,  
c +, efficious; -, inefficious;  
d, Ig, immunoglobin 
 
 
It was Dr. Michael Sporn who first coined the term chemoprevention in the 
1970s as part of his pioneering effort to encourage research into preventing 
cancer before it begins rather than treating tumors once they appear [28]. 
According to a more modern and complete definition, chemoprevention includes 
the use of natural or pharmacological agents to suppress, arrest or reverse 
carcinogenesis, at its early stages. In this regard, a significant correlation 
between dietary intake and many types of cancer has been shown in 
epidemiological data generated throughout the world, pointing towards potent 
anticancer properties of many dietary substances. However, in many cases, the 
chemopreventive effects of natural occurring phytochemicals are primarily 
based on cell culture and animal model studies, and only few of them are 
entering clinical trials.  
For many years, the naturally occurring polyphenol Resveratrol attracted little 
interest until it was postulated to explain some of the cardioprotective effects of 
red wine. Since then, more and more reports were published, showing, that 
resveratrol can prevent or slow the progression of a wide variety of diseases, 
including cancer. The observed effects of resveratrol on multiple signal 
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transduction pathways related to carcinogenesis has generated tremendous 
interest in evaluating its potential for use as a clinical chemopreventive and 
chemotherapeutic agent. By contrast results from pharmacokinetic studies 
indicate that circulating resveratrol is rapidly metabolized, and cast doubt on the 
physiological relevance of the high concentrations typically used for in vitro 
experiments. However, systemic administration of resveratrol has been shown 
to inhibit the initiation and growth of tumors in a wide variety of rodent cancer 
models (Summarized in Table 2).  
Overall, these in vivo studies clearly show great promise for this molecule in the 
treatment and prevention of cancers. The observed efficacy of low doses, for 
example 200µg/kg body weight/day, which counteracted azoxymethane-
induced carcinogenesis in a rat model of colon cancers, suggests that even 
concentrations of resveratrol, which might be achievable from dietary sources, 
such as red wine, could be therapeutic in some cases [209]. But protective 
effects of resveratrol are more dramatic at higher, but pharmacological 
achievable doses. Therefore, from a functional, pharmacological and clinical 
point of view it would be useful to distinguish between “pharmacological” and 
“dietary” chemoprevention. 
The question remains whether the observed effects in vitro and in vivo using 
animal models are also conferrable and relevant for humans. Several phase I 
clinical trials are currently in progress for oral resveratrol administration in 
humans to respond this issue. At the National Cancer Institute chemopreventive 
effects of resveratrol are measured in a multicenter study, where cohorts of 10 
participants receive escalating doses of resveratrol (up to 5g/day) until the 
maximum tolerated dose (MTD) is determined. 
(http://www.cancer.gov/clinicaltrials/CCUM-2004-0535).  
In addition to chemopreventive properties a chemotherapeutic potential is 
presumed, as molecular targets of resveratrol are similar to those currently 
being used for the treatment of cancer [213]. At the University of California, 
phase I and II studies are in progress supplementing Resveratrol to Patients 
already diagnosed with colon cancer.  
(http://www.clinicaltrials.gov/ct/show/NCT00256334).  
Despite aggressive therapies, resistance of many tumors to established 
treatment procedures still constitutes a major problem in cancer therapy. 
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Recent evidence suggests that the use of resveratrol in combination with drugs, 
ionizing radiation or cytokines, can be effectively used for the sensitization to 
apoptosis. Resveratrol was shown to sensitize to various cytotoxic agents such 
as cyclosporine A [214], paclitaxel [215], 5-FU [216;217], cisplatin and 
doxorubicin [218]. Concerning cytokines, several works have shown that 
resveratrol is also able to sensitize to TRAIL-induced apoptosis in cancer cells 
[219;220]. Hence, and because of its pharmacological safety, resveratrol might 
be used in combination with chemotherapeutic agents to exert enhanced 
antitumor activity through synergic action or compensation of inverse properties. 
The combined treatment may also decrease the systemic toxicity caused by 
chemotherapies or radiotherapies because lower doses could be used.  
As a result of the discovery of the interesting pharmacological properties of 
resveratrol, the trihydroxystilbene scaffold has become the subject of synthetic 
manipulations with the aim of generating novel congeners of pharmacological 
interest especially those with potential chemotherapeutic activities. In this 
context, efforts have been devoted to the detailed study of the structure-activity 
relationship. Some derivatives, for example 3,4,5,4’-tetrahydroxystilbene 
exhibits superior availability compared to resveratrol with potent biological 
effects [221]. A series of cis- and trans stilbene derivatives were prepared by 
Roberti et al. and were tested in vitro for cell growth inhibition and the ability to 
induce apoptosis in leukaemia cells. Interestingly, all the tested trans-stilbene 
analogues were less potent than their corresponding cis isomers exepting trans-
resveratrol, whose cis counterpart was inactive [222]. This is in accordance with 
our findings showing 100fold higher effectiveness of a Trimethoxy-cis-stilbene 
compared to the parent compound in our colon cancer model (unpublished 
data). Deciphering the structural determinants which are responsible for the 
biological activity of resveratrol together with the observation that miscellaneous 
structural modifications generate higher chemopreventive activity and 
bioavailability provide useful information for new potential chemopreventive or 
chemotherapeutic drug design.  
Due to all these properties, resveratrol seems to be an auspicious candidate in 
chemoprevention or in chemotherapeutic approaches and could be a potential 
compound in the development of new therapeutic strategies. 
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Abstract
Previous results indicate that the polyphenol resveratrol
inhibits cell growth of colon carcinoma cells via modulation
of polyamine metabolic key enzymes. The aim of this work was
to specify the underlying molecular mechanisms and to
identify a possible role of transcription factor peroxisome
proliferator–activated receptor ; (PPAR;). Cell growth was
determined by bromodeoxyuridine incorporation and crystal
violet staining. Protein levels were examined by Western
blot analysis. Spermine/spermidine acetyltransferase (SSAT)
activity was determined by a radiochemical assay. PPAR;
ligand–dependent transcriptional activity was measured by a
luciferase assay. A dominant-negative PPAR; mutant was
transfected in Caco-2 cells to suppress PPAR;-mediated
functions. Resveratrol inhibits cell growth of both Caco-2
and HCT-116 cells in a dose- and time-dependent manner
(P < 0.001). In contrast to Caco-2-wild type cells (P < 0.05),
resveratrol failed to increase SSAT activity in dominant-
negative PPAR; cells. PPAR; involvement was further
confirmed via ligand-dependent activation (P < 0.01) as well
as by induction of cytokeratin 20 (P < 0.001) after resveratrol
treatment. Coincubation with SB203580 abolished SSAT
activation significantly in Caco-2 (P < 0.05) and HCT-116
(P < 0.01) cells. The involvement of p38 mitogen-activated
protein kinase (MAPK) was further confirmed by a resvera-
trol-mediated phosphorylation of p38 protein in both cell
lines. Resveratrol further increased the expression of PPAR;
coactivator PGC-1A (P < 0.05) as well as SIRT1 (P < 0.01) in
a dose-dependent manner after 24 hours of incubation.
Based on our findings, p38 MAPK and transcription factor
PPAR; can be considered as molecular targets of resveratrol
in the regulation of cell proliferation and SSAT activity,
respectively, in a cell culture model of colon cancer. (Cancer
Res 2006; 66(14): 7348-54)
Introduction
Resveratrol is a naturally occurring polyphenol present in red
wine, peanuts, and grapes (1, 2). It has been speculated that dietary
resveratrol could be an explanation for the so-called ‘‘French
paradox,’’ as it exhibits multiple cardioprotective properties (3, 4).
Furthermore, we and others reported potent chemopreventive
effects of resveratrol and its analogues in various carcinogenesis
models (5–8). The polyamines spermidine and spermine as well as
their precursor putrescine are essential for normal cell growth,
development, and tissue repair (9, 10). Correlation of excess
polyamine levels with cancer was first reported in the late 1960s,
when Russel and Snyder (11) reported high levels of ornithine
decarboxylase activity, the pivotal enzyme of polyamine biosyn-
thesis, in several human cancers. In colorectal cancer tissue,
polyamine contents are increased 3- to 4-fold over that found in the
equivalent normal colonic tissue (12, 13). Based on these findings,
pharmacologic or natural inhibitors of polyamine metabolism have
been studied in vitro (13, 14) and in vivo (15) as new potent
therapeutic strategies in cancer treatment and prevention.
Peroxisome proliferator–activated receptors (PPARs) are ligand-
inducible transcription factors belonging to the nuclear hormone
receptor superfamily (16, 17), which regulate transcription of target
genes by heterodimerizing with the retinoid X receptor and binding
to PPAR response elements (16, 18). PPARg is expressed at high
levels in colonic epithelial cells and colon cancer cells (19). Girnun
and Spiegelman (20) hypothesize that PPARg is exerting its effects
early in the carcinogenic process by suppressing tumor formation.
Activation of PPARg therefore could function as an important
molecular target of chemopreventive agents such as resveratrol.
Recently, Babbar et al. (21) identified two PPAR response elements
in the promoter of the spermine/spermidine acetyltransferase
(SSAT) gene. Based on our former findings that resveratrol induces
cell growth inhibition of colon cancer cells via induction of
catabolic enzyme SSAT (13), the aim of this work was to specify the
underlying molecular mechanisms and to identify a possible role of
transcription factor PPARg.
Materials and Methods
Cell Culture and Materials
Caco-2 cells of passages 53 to 61 were kept in DMEM, supplemented with
10% FCS, 1% penicillin/streptomycin, 1% sodium pyruvate, and 1%
nonessential amino acids. HCT-116 cells of passages 17 to 30 were cultured
in McCoy’s 5A supplemented with 10% FCS and 1% penicillin/streptomycin.
Both cell lines were maintained at 37jC in an atmosphere of 95% air and 5%
CO2. Cos7 cells were cultured in DMEM high-glucose supplemented with
10% FCS containing 100 units/mL penicillin, 100 Ag/mL streptomycin,
2 mmol/L glutamine, and 1 mmol/L sodium pyruvate at 37jC and 10% CO2.
The cells were passaged weekly using Dulbecco’s PBS containing 0.25%
trypsin and 1% EDTA. The medium was changed thrice per week. Cells were
screened for possible contamination with mycoplasma at monthly intervals.
For experiments, the cells were seeded onto plastic cell culture wells in
serum-containing medium and allowed to attach for 24 hours. For the SSAT
activity assay, the cells were synchronized in medium containing 1% FCS 24
hours before treatment. WY-14643, pioglitazone HCl, L-165,041, GW7647,
and SB203580 were obtained from Calbiochem (San Diego, CA); resveratrol
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was obtained from Sigma-Aldrich; FCS and DMSO were obtained from
Sigma; DMEM and Optimem I from Life Technologies, Inc.; sodium
pyruvate solution, glutamine, penicillin, and streptomycin stock solutions
from PAA Laboratories GmbH; Lipofectamine 2000 from Invitrogen; and
Dual-glo Luciferase Assay system from Promega.
SDS-PAGE and Immunoblot Analysis
Caco-2 cells were seeded in 80-cm2 flasks; 24 hours after plating, cells
were incubated with substances for different time intervals. Cytosolic and
nuclear extracts were obtained according to the instructions of the
manufacturer (Active Motif, Rixensart, Belgium). Protein was quantified
with the Bio-Rad protein colorimetric assay. After addition of sample buffer
to the cellular extract and boiling samples at 95jC for 5 minutes, protein
was separated on 10% SDS-polyacrylamide gel. Protein was transferred onto
nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) and the
membrane was blocked for 1 hour at room temperature with 3% skim milk
in Tris-buffered saline containing 0.05% Tween 20 (TBST). Next, blots were
washed and incubated overnight at 4jC in TBST containing either 5% bovine
serum albumin or 3% milk skim powder with a 1:1,000 or 1:500 dilution of
primary antibodies for p38 and phospho-p38 (all from Cell Signaling, Beverly,
MA), SIRT1, PGC-1a, and cytokeratin 20 (all from Santa Cruz Biotechnology,
Santa Cruz, CA), and PPARg (Calbiochem). The horseradish peroxidase–
conjugated secondary antibody (Santa Cruz Biotechnology) was diluted at
1:2,000 and incubated with the membrane for another 30 minutes in skim
milk. After chemiluminescence reaction (ECL; Amersham Pharmacia
Biotech, Buckinghamshire, United Kingdom), bands were detected after
exposure to Hyperfilm-MP (Amersham International plc, Buckinghamshire,
United Kingdom). Blots were reprobed with h-actin antibody (Santa Cruz
Biotechnology). For quantitative analysis, bands were detected and evaluated
densitometrically with ProViDoc system (Desaga, Wiesloch, Germany),
normalized for h-actin density.
Cell Counts
Cells were suspended and cultured on 96-well dishes at a density of 104
per well (0.28 cm2). Twenty-four hours after plating, cells were incubated for
24 to 72 hours with substances. At given time points following treatment, cell
numbers were assessed by crystal violet staining. Medium was removed from
the plates and cells were fixed with 5% formaldehyde for 5 minutes. After
washing with PBS, cells were stained with 0.5% crystal violet for 10 minutes,
washed again with PBS, and unstained with 33% acetic acid. Absorption,
which correlates with the cell number, was measured at 620 nm.
Cell Proliferation
The effects of resveratrol on DNA synthesis of cells were assessed using
the cell proliferation ELISA kit (Roche Diagnostics, Tokyo, Japan). This assay
is a colorimetric immunoassay for quantification of cell proliferation based
on the measurement of bromodeoxyuridine (BrdUrd) incorporation during
DNA synthesis and is a nonradioactive alternative to the [3H]thymidine
incorporation assay. Cells were grown in 96-well culture dishes (104 per
well), incubated with resveratrol for different time intervals, and then
labeled with BrdUrd for a further 4 hours. Incorporated BrdUrd was
measured colorimetrically.
SSAT Enzyme Activity Determination
Cells were washed twice with cold homogenizing buffer [10 mmol/L
Tris-HCl (pH 7.5), 2.5 mmol/L DTT, 1 mmol/L EDTA], harvested by
Figure 1. Cell counts and cell proliferation of HCT-116
cells 24, 48, and 72 hours after incubation without (control)
or with resveratrol (30-200 Amol/L). Resveratrol leads to a
conspicuous dose- and time-dependent reduction of cell
counts as well as an inhibition of cell proliferation.
Columns, mean (n = 8); bars, SE. ***, P < 0.001.
Figure 2. Activity of SSAT in Caco-2-wild type cells in comparison
with transfected Caco-2-empty vector and Caco-2-dnPPARg cells
after incubation with resveratrol (50-100 Amol/L) for 24 hours.
Resveratrol leads to a significant increase both in Caco-2-wild type
and Caco-2-empty vector cells. However, no effects could be
observed when PPARg-mediated functions are suppressed.
Columns, mean (n = 4); bars, SE. Values not sharing a letter differ
significantly (P < 0.05).
Resveratrol in Colorectal Cancer
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scraping, disrupted by sonification, and centrifuged at 15,000  g at 4jC for
15 minutes. The radiochemical assay of the SSAT activity was done by the
estimation of labeled N1-acetylspermidine synthesized from [14C]acetyl-CoA
(Hartman Analytic, Braunschweig, Germany) and unlabeled spermidine
(0.3 Amol/L) as described earlier (13).
Transfection Assay
The following plasmids were used for transfection: pcDNA3 (Invitrogen),
as an empty vector for control transfection, and plasmid pcDNA3-
PPARgL468A/E471A, a dominant-negative double mutant, which was kindly
provided by V.K. Chatterjee (Department of Medicine, University of
Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom; ref. 22).
These constructs were transfected into subconfluent Caco-2 cells with
Lipofectamine 2000 (Invitrogen). After 6 hours, the cells were fed with fresh
medium containing 10% FCS. Twenty-four hours later, the cells were fed
with medium containing G418 (400 Ag/mL) and culture medium was
replaced twice a week. G418-resistant colonies were collected and used for
further analysis.
Gal4-PPAR; Transactivation Assay
Plasmids. The Gal4-fusion receptor plasmid pFA-CMV-PPARg-LBD,
containing hinge region and the LBD of PPARg, was constructed by
integrating cDNA fragment obtained from PCR amplification of human
monocytes into the SmaI/XbaI (Promega) sites of the pFA-CMV vector
(Stratagene). The cDNA fragment contained bps 610-1,518 (NM_015869) of
the PPARg coding sequence. Frame and sequence of the fusion receptors
Figure 3. A, induction of a GAL4-driven
luciferase reporter gene following
ligand-dependent activation of a
Gal4-PPARg fusion receptor in transiently
transfected Cos7 cells. Graph plots fold
induction by resveratrol or pioglitazone at
indicated concentration. Each experiment
was done in triplicate and repeated in two
independent experiments. Columns, mean;
bars, SE. #, not significant; *, P < 0.05;
**, P < 0.01. B, Western blot of cytokeratin
20 in Caco-2 cells after incubation with
resveratrol (30-100 Amol/L) for 72 hours.
Representative immunoblot of three
independent experiments. Graph presents
the densitometric analysis of cytokeratin
20 after 72 hours of incubation. Columns,
mean (n = 3); bars, SE. ***, P < 0.001.
Figure 4. A, Western blot of p38 and phosphorylated p38
MAPK protein in Caco-2 cells after incubation with
resveratrol (50-200 Amol/L) for 6 and 16 hours.
Representative immunoblot of three independent
experiments for both proteins. Graph presents the
densitometric analysis of phospho-p38/p38 protein ratio
after 6 and 16 hours. Columns, mean (n = 3); bars, SE.
#, not significant; *, P < 0.05; **, P < 0.01. B, Western blot
of p38 and phosphorylated p38 MAPK protein in HCT-116
cells after incubation with resveratrol (50-200 Amol/L) for
6 and 16 hours. Representative immunoblot of three
independent experiments for both proteins. Graph
presents the densitometric analysis of phospho-p38/p38
protein ratio after 6 and 16 hours. Columns, mean (n = 3);
bars, SE. #, not significant; *, P < 0.05; **, P < 0.01.
Cancer Research
Cancer Res 2006; 66: (14). July 15, 2006 7350 www.aacrjournals.org
were verified by sequencing. As reporter plasmids, we used pFR-Luc
(Stratagene). For normalizing of transfection efficacy, we used pRL-SV40
(Promega).
Transfection. Cos7 cells were seeded at 30,000 per well in a 96-well
plate. After 24 hours, transfection was carried out using Lipofectamine 2000
according to the protocol of the manufacturer. Transfection mixes
contained 0.8 AL LF2000, 280 ng pFR-Luc, 2 ng pRL-SV40, and 14 ng
of the PPARg fusion receptor plasmid for each well. Four hours after
transfection, medium was changed to DMEM without phenol red–
containing 100 units/mL penicillin, 100 Ag/mL streptomycin, 2 mmol/L
glutamine, 1 mmol/L sodium pyruvate, appropriate concentration of test
substance, and 0.1% DMSO, testing each concentration in triplicate wells.
Cells were incubated overnight and assayed for reporter gene activity
with the Dual-Glo Luciferase Assay system. Luminescence of both
luciferases was measured in GENiosPro Luminometer (Tecan). Each assay
was repeated at least thrice.
Calculations. Luciferase activity for all assays was corrected by
subtracting background activity obtained from nontransfected controls.
Relative light units were calculated by dividing firefly light units by renilla
light units. Activation factors are gained by dividing mean values of relative
light units for each concentration of agonist by mean relative light unit
values of the DMSO control. Relative activation is calculated by dividing
activation factors by the maximum activation factor. Calculation of EC50
values was done using the four-parameter logistic regression function of
SigmaPlot2001 (SPSS, Inc.) using the mean of relative activation for each
tested concentration of at least three determinations.
Statistics
The data are expressed as means F SE of at least three independent
experiments. ANOVA was done when more than two groups were
compared, and when significant (P < 0.05), multiple comparisons were
done with the Turkey test. P < 0.05 was considered to be significant.
Results
Effects of resveratrol on cell proliferation and cell counts.
Caco-2 and HCT-116-cells were incubated with increasing concen-
trations of resveratrol (30-200 Amol/L) for 24, 48, and 72 hours.
After each time interval, both cell proliferation ELISA (BrdUrd) and
crystal violet staining were done. In HCT-116 cells, a significant
time- and dose-dependent decrease in cell proliferation and cell
counts could be measured (Fig. 1). The same effects could be
observed in Caco-2 cells, which is in accordance to our earlier
studies (ref. 6; data not shown).
The role of PPAR; in resveratrol-induced activation of
SSAT. Next, we examined the effects of resveratrol (50-100 Amol/L)
on SSAT activity in Caco-2-wild type cells compared with Caco-2-
empty vector and Caco-2-dnPPARg mutant cells to investigate
effects mediated by PPARg. Resveratrol (100 Amol/L) leads to a
significant increase of SSAT activity (P < 0.05 versus control) in
Caco-2-wild type cells after 24 hours of incubation, which is in
agreement with our previous data (13). In Caco-2-empty vector
cells, resveratrol (100 Amol/L) also significantly increases SSAT-
activity (P < 0.05 versus control) whereas no effects could be
observed when PPARg-mediated functions are suppressed in Caco-
2-dnPPARg mutant cells (Fig. 2).
Effects of resveratrol on PPAR; transcriptional activity.
To investigate the effects of resveratrol (50-100 Amol/L) on PPARg
ligand–dependent activity, we did a chimeric Gal4-PPARg trans-
activation assay. Because the chimeric receptor contained only
hinge region and ligand binding domain of the PPARg, any effect of
resveratrol affecting kinase-sensitive AF1 domain was ruled out.
After incubation with resveratrol (100 Amol/L), we could generate
similar effects of PPARg agonist pioglitazone on PPARg activity
(P < 0.01; Fig. 3A). To show evidence of resveratrol ability to
increase PPARg activity, we measured, after resveratrol treatment,
the expression of cytokeratin 20, which is described to be a specific
target gene of PPARg activity in colorectal cancer cells (23).
Incubation with resveratrol (30-100 Amol/L) led to an f40%
increase of cytokeratin 20 expression at 100 Amol/L after 72 hours
(P < 0.001; Fig. 3B).
Effects of resveratrol on PPAR; protein levels.We further did
Western blot analysis to determine possible effects of resveratrol
on translational level. However, no significant changes in PPARg
protein expression could be detected (data not shown).
Involvement of mitogen-activated protein kinase p38 in
resveratrol-induced inhibition of cell proliferation and SSAT
activation. There are several lines of evidence that resveratrol
Figure 5. A, coincubation with SB203580 (20 Amol/L) abolishes resveratrol
(100 Amol/L)–induced SSAT activation significantly in Caco-2 cells after 24 hours
of incubation. Columns, mean (n = 4); bars, SE. *, P < 0.05. B, the same effects
could be observed in HCT-116 cells when inhibition of p38 MAPK (10 Amol/L)
significantly reduces resveratrol-induced SSAT activity after 24 hours of
incubation, indicating the effects not to be cell specific. Columns, mean (n = 4);
bars, SE. **, P < 0.01.
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mediates its chemopreventive actions via modulation of mitogen-
activated protein kinase (MAPK) pathways. To examine p38
MAPK–mediated actions, we used the specific inhibitor
SB203580. This anti-inflammatory drug inhibits the catalytic
activity of p38 MAPK by competitive binding in the ATP pocket
(24). As shown in Fig. 4, incubation with resveratrol (50-200 Amol/L)
augmented phosphorylated p38 in a time- and dose-dependent
manner, both in Caco-2 and HCT-116 cells (f300% at 200 Amol/L
after 16 hours; P < 0.01), whereas p38 MAPK concentration
remained unaffected. To characterize the role of p38 activation in
resveratrol-mediated induction of SSAT, we pretreated Caco-2 and
HCT-116 with p38 inhibitor SB203580 (10-20 Amol/L) for 1 hour
and then added resveratrol (100 Amol/L) for another 24 hours. Both
in Caco-2-(Fig. 5A) and HCT-116-cells (Fig. 5B), coincubation with
SB203580 significantly diminished resveratrol-induced SSAT acti-
vation [P < 0.05 versus resveratrol (100 Amol/L) in Caco-2; P < 0.01
versus resveratrol (100 Amol/L) in HCT-116].
Effects of resveratrol on PGC-1A and SIRT1 expression.
Western blot analysis was done to determine possible effects of
resveratrol on the expression of PPARg coactivator 1a and sirtuin
homologue SIRT1, which exhibits PPARg-suppressive effects in
white adipocyte tissue. Resveratrol (50-200 Amol/L) led to a
significant dose-dependent increase in both PGC-1a (f60% at
200 Amol/L; P < 0.05; Fig. 6A) and SIRT1 (f140% at 200 Amol/L;
P < 0.01; Fig. 6B) expression after 24 hours of incubation.
Discussion
The present study clearly shows that resveratrol mediates
growth inhibitory effects in colorectal cancer cell lines, at least
partly, via polyamine degradation, whereas activation of transcrip-
tion factor PPARg seems to play a pivotal role. The plant
polyphenol resveratrol (3,4¶,5-trihydroxystilbene) exhibits multiple
chemopreventive effects comprising cell growth inhibition (6, 25),
induction of apoptosis (26), and prevention of angiogenesis (27),
whereby the underlying molecular mechanisms are only partly
understood (28, 29). Intracellular polyamine levels are maintained
within very narrow limits because decreases of polyamine con-
centrations interfere with cell growth whereas an excess seems to
be toxic (30). The three key enzymes of polyamine metabolism are
ornithine decarboxylase and S-adenosylmethionine decarboxylase,
the rate-limiting enzymes of polyamine biosynthesis, and SSAT,
which controls polyamine catabolism (31). Wolter et al. showed
that resveratrol-induced growth arrest of Caco-2 cells is accompa-
nied by inhibition of polyamine biosynthesis as well as activation of
polyamine catabolism (13). The peroxisome proliferator–activated
receptor g (PPARg) is a nuclear receptor that acts as a tran-
scription factor controlling the expression of multiple genes
involved in cell growth, differentiation, and apoptosis of several
malignant cell lines, and therefore seems to play a crucial role in
carcinogenesis (32, 33). To abolish PPARg-mediated functions, we
transfected a dominant-negative mutant in Caco-2 cells. In this
PPARg mutant, two charged amino acid residues (Leu468 and
Glu471) in helix 12 of the ligand binding domain are mutated to
alanine, whereupon the mutant retains ligand and DNA binding
but exhibits markedly reduced transactivation due to impaired
coactivator recruitment (22). According to the current findings, an
essential role for PPARg in enhancing SSAT enzyme activity is
assumed (21). In fact, we could show that, in contrast to Caco-2-
wild type and Caco-2-empty vector cells, resveratrol failed to
increase SSAT activity in Caco-2-dnPPARg cells. The mitogen-
activated protein kinase (MAPK) pathways have been recognized
as a major signaling pathway by which cells transduce extracellular
signals into an intracellular response. In several studies, resveratrol
was shown to mediate multiple functions by modulating MAPK
pathways (26, 34, 35). We could show as well that incubation with
resveratrol causes phosphorylation, and thus activation, of p38
MAPK in colon cancer cells. Furthermore, combination of
resveratrol with an inhibitor of p38 MAPK leads to an inhibition
of resveratrol-induced SSAT activation both in Caco-2 and HCT-116
cells. Consequently, an activation of MAPK cascade by resveratrol
can be assumed. As previously described, our results point out an
Figure 6. Western blot of PGC-1a protein in
Caco-2 cells after incubation with resveratrol
(50-200 Amol/L) for 24 hours. Graph
presents the densitometric analysis of
PGC-1a protein after 24 hours.
Representative immunoblot of three
independent experiments. Columns, mean
(n = 3); bars, SE. *, P < 0.05. B, Western
blot of SIRT1 protein in Caco-2 cells after
incubation with resveratrol (50-200 Amol/L)
for 24 hours. Graph presents the
densitometric analysis of SIRT1 protein ratio
after 24 hours. Representative immunoblot
of three independent experiments. Columns,
mean (n = 3); bars, SE. *, P < 0.05;
**, P < 0.01.
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important role of PPARg in resveratrol-mediated actions whereas
resveratrol-dependent PPARg activation seems to be mediated at
least partly by an activation of the ligand binding domain (LBD/
AF2) because a Gal4-PPARg chimeric receptor was activated by
resveratrol at a concentration of 100 Amol/L, and this concentra-
tion was sufficient to induce SSAT as well. In addition, our results
suggest that activation of PPARg by resveratrol is due to kinase
activation, leading to phosphorylation-dependent activation of
PPARg coactivators like PGC-1a (36). Coactivators all interact with
a similar surface of the activated ligand binding domain of the
receptors and have been suggested to mediate their transcriptional
activity (37). It is well established that, in addition to transcription
factors, coactivators can also be targets of multiple signal
transduction pathways in response to different stimuli (38).
Puigserver et al. (39) could show that PGC-1a is activated through
p38 MAPK. The mechanism by which p38 activates PGC-1a is not
yet clear, but it is suggested that p38 MAPK–mediated phosphor-
ylation counteracts repressor effects, possibly by encouraging the
release of a repressor from PGC-1a (40). On activation, PGC-1a
docks on PPARg and thus can modulate its transcriptional activity
(41). In addition to PGC-1a, resveratrol further leads to an
activation of SIRT1, a member of the silent information regulator 2
(Sir2) family of proteins (sirtuins; ref. 42). SIRT1 is mainly linked to
negative regulation of gene expression as a cofactor through
protein deacetylation (43). However, there is evidence that SIRT1
can act positively and negatively to control gene expression as a
cofactor for PGC-1a. These opposite effects could possibly be due
to the recruitment of a different set of coactivators and
corepressors through PGC-1a/SIRT1 (44). This could further be
an explanation for the repressive effects of SIRT1 on PPARg in
white fat where PGC-1a is very low (45). In summary, our data
confirm our earlier studies showing that resveratrol-mediated
growth inhibition of colorectal cancer cells seems to involve SSAT-
induced polyamine catabolism. Here we further show that
transcription factor PPARg acts as a p38-dependent target in
resveratrol-induced molecular mechanisms (see Fig. 7). Besides a
decrease in cell proliferation, the observed reduction of BrdUrd
incorporation is probably due to an induction of apoptosis, as
Wolter et al. (6) showed an obvious increase of caspase-3-activity in
resveratrol-treated cells. Recent studies further indicate that the
activation of catabolic SSAT is related to an induction of
programmed cell death (46). Further projects directing towards
these aspects of resveratrol action are going to proceed.
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Previous studies could demonstrate, that the naturally occuring polyphenol resveratrol
inhibits cell growth of colon carcinoma cells at least in part by inhibition of protooncogene
ornithine decarboxylase (ODC). The objective of this study was to provide several lines of
evidence suggesting that the induction of ceramide synthesis is involved in this regulatory
mechanisms.
Cell growth was determined by BrdU incorporation and crystal violet staining. Ceramide
concentrations were detected by HPLC-coupled mass-spectrometry. Protein levels were
examined by Western blot analysis. ODC activity was assayed radiometrically measuring
[14CO2]-liberation. A dominant-negative PPARg mutant was transfected in Caco-2 cells to
suppress PPARg-mediated functions.
Antiproliferative effects of resveratrol closely correlate with a dose-dependent increase
of endogenous ceramides ( p < 0.001). Compared to controls the cell-permeable ceramide
analogues C2- and C6-ceramide significantly inhibit ODC-activity (p < 0.001) in colorectal
cancer cells. C6-ceramide further diminished protein levels of protooncogenes c-myc
( p < 0.05) and ODC ( p < 0.01), which is strictly related to the ability of ceramides to inhibit
cell growth in a time- and dose-dependent manner. These results were further confirmed
using inhibitors of sphingolipid metabolism, where only co-incubation with a serine
palmitoyltransferase (SPT) inhibitor could significantly counteract resveratrol-mediated
actions. These data suggest that the induction of ceramide de novo biosynthesis but not
hydrolysis of sphingomyelin is involved in resveratrol-mediated inhibition of ODC. In
contrast to the regulation of catabolic spermidine/spermine acetyltransferase by resvera-
trol, inhibitory effects on ODC occur PPARg-independently, indicating independent path-
ways of resveratrol-action. Due to our findings resveratrol could show great
chemopreventive and therapeutic potential in the treatment of colorectal cancers.
# 2007 Elsevier Inc. All rights reserved.* Corresponding author. Tel.: +49 69 6301 5917; fax: +49 69 6301 83112.
E-mail address: j.stein@em.uni-frankfurt.de (J.M. Stein).
Abbreviations: BrdU, bromodeoxyuridine; DMEM, Dulbecco’s modified Eagle’s medium; DFMO, alpha-difluoromethylornithine;
dnPPARg, dominant negative PPARg mutant; ELISA, enzyme-linked immunosorbent assay; MAPK, mitogen-activated protein kinase;
NSAID, non-steroidal anti-inflammatory drugs; ODC, ornithine decarboxylase; PAO, polyamine oxidase; PPARg, peroxisome-proliferator
activated receptor g; RXR, retinoid X receptor; SAMDC, S-adenosylmethioninedecarboxylase; SMase, Sphingomyelinase; SPT, serine
palmitoyltransferase; SSAT, spermine/spermidine acetyltransferase; TNF-a, tumor necrosis factor-a
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Resveratrol, chemically known as 3,5,40-trihydroxytransstil-
bene, is a naturally occuring polyphenolic antioxidant
compound, also classified as a phytoalexin, which are herbal
antibiotics produced in response to environmental stress
factors including injuries, UV irradiation or fungal invasion [1].
Resveratrol was first detected in the root extract of the weed
Polygonum cuspidatum [2], which has been known in Asian
folk medicine under the name Ko-jo-kon and was traditionally
used to treat liver, skin and circulatory diseases [3,4]. Anti-
carcinogenic properties of resveratrol were first reported by
Jang et al. [5] demonstrating chemopreventive effectiveness
against all the three major steps of carcinogenesis, i.e.
initiation, promotion and progression. We and others provide
several lines of evidence that resveratrol mediates these anti-
carcinogenic effects partly through the modulation of poly-
aminemetabolism[6,7]. Themajorpolyaminesspermidineand
spermine, and their diamine precursor, putrescine are organic
cations with multiple functions in cell growth and cell death
[8,9]. The intracellular polyamine pool size is controlled strictly
by thecombinedactionofde novo synthesis, catabolism,uptake
and export of polyamines. This regulatory mechanism
include reactions catalyzed by the biosynthetic enzymes
ornithine decarboxylase (ODC), S-adenosylmethionine decar-
boxylase (SAMDC) and spermidine/spermine synthases and by
the catabolic spermidine/spermine acetyltransferase (SSAT)
and FAD-dependent polyamine oxidase (APAO) [10]. The
finding that agents that inhibit polyamine biosythesis can
prevent, or at least limit cell growth [6,11–13], togetherwith the
fact, that polyamine concentrations are elevated in multiple
cancer tissues [14,15], has made the polyamine metabolism a
promising target for cancer chemoprevention and therapy.
Ceramides are key compounds in the metabolism of
sphingolipids and are emerging as important second mes-
sengers for various cellular processes including cell cycle
arrest, differentiation and apoptosis (for review see Ref. [16]).
Ceramides can be produced via a de novo biosynthetic pathway
which is initiated by condensation of serine and palmitoyl-
CoA catalyzed by serine palmitoyltransferase (SPT) as well as
by sphingomyelinase-mediated hydrolysis of sphingomyelin.
Our aim was to study the potential involvement of ceramide
biosynthesis in resveratrolmediated inhibition of ODC activity
in colorectal cancer cells.2. Materials and methods
2.1. Cell culture and materials
Caco-2cells of passages53–61werekept inDulbecco’smodified
Eagle’s medium (DMEM), supplemented with 10% fetal calf
serum (FCS), 1% penicillin/streptomycin, 1% sodium pyruvate
and 1% nonessential amino acids. HT29 cells of passages 17–30
were cultured in McCoy’s 5A supplemented with 10% FCS and
1% penicillin/streptomycin. Both cell lines were maintained at
37 8C in an atmosphere of 95% air and 5% CO2. The cells were
passagedweeklyusingDulbecco’sPBScontaining0.25%trypsin
and 1% EDTA. The medium was changed three times per
week. Cells were screened for possible contamination withmycoplasma at monthly intervals. For experiments, the cells
were seeded onto plastic cell culture wells in serum containing
medium and allowed to attach for 24 h. For the ODC activity
assay the cells were synchronized in medium containing 1%
FCS 24 h before treatment. Resveratrol, N-hexanoylsphingo-
sine, N-acetylsphingosine, L-cycloserine, myriocin and manu-
mycin were obtained from Sigma–Aldrich (St. Louis, MO);
Dulbecco’s modified Eagle’s medium and OptimemTM I from
Gibco (Invitrogen, Carlsbad, CA); fetal calf serum, sodium
pyruvate solution, glutamine, penicillin and streptomycin
stock solutions from PAA Laboratories GmbH (Ontario,
Canada); LipofectamineTM 2000 from Invitrogen (Carlsbad, CA).
2.2. SDS-polyacrylamide gel electrophoresis and
immunoblot analysis
Caco-2cellswereseeded in80 cm3flasks; 24 hafterplating, cells
were incubated with substances for different time intervals.
Whole cell extract was obtained according to the manufac-
turer’s instructions (Active Motif, Rixensart, Belgium). Protein
was quantified with the Bio-Rad protein colorimetric assay.
After addition of sample buffer to the total cellular extract and
boiling samples at 95 8C for 5 min, protein was separated on a
10% SDS-polyacrylamide gel. Protein was transferred onto
nitrocellulose membrane (Schleicher&Schuell, Dassel, Ger-
many) and the membrane was blocked for 1 h at room
temperature with 3% skimmilk in tris-buffered saline contain-
ing 0.05% Tween 20 (TBST). Next, blots were washed and
incubated overnight at 4 8C in TBST containing 3% skimmed
milkpowderwitha 1:500dilutionofprimaryantibodies forODC
and c-myc (all from Santa Cruz Biotechnology, Santa Cruz,
USA). The secondary, horseradish peroxidase-conjugated anti-
body (Santa Cruz Biotechnology) was diluted at 1:2000 and
incubatedwith themembrane for another 45 min in skimmilk.
After chemoluminescence reaction (ECL, Amersham Pharma-
cia Biotech, Buckinghamshire, UK), band were detected after
exposure to Hyperfilm-MP (Amersham International plc, Buck-
inghamshire, UK). Blots were reprobed with b-actin antibody
(Santa Cruz Biotechnologies, Santa Cruz, USA). For quantitative
analysis, bands were detected and evaluated densitometrically
by ProViDoc system (Desaga, Wiesloch, Germany), normalized
for the density of b-actin.
2.3. Cell counts
Cells were suspended and cultured on 96 well dishes at a
density of 104/well (0.28 cm2). Twenty-four hours after plating
cells were incubated for 24–72 hwith ceramides. At given time
points following treatment cell numbers was assessed by
crystal violet staining. Medium was removed from the plates
and cells were fixed with 5% formaldehyde for 5 min. After
washing with PBS cells were stained with 0.5% crystal violet
for 10 min, washed again with PBS and unstained with 33%
acetic acid. Absorption, which correlateswith the cell number,
was measured at 620 nm.
2.4. Cell proliferation
The effects of ceramides on DNA synthesis of cells were
assessed using the cell proliferation ELISA kit (Roche Diag-
Fig. 1 – Synthesis of C16-ceramide in Caco-2-wildtype cells
after incubation with resveratrol [50–200 mmol/L] for 24 h.
Resveratrol significantly enhances the intracellular C16-
ceramide concentration in a dose-dependent manner.
MeansW S.E.; n = 4; **p < 0.01; ***p < 0.001 vs. control.
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noassay for quantification of cell proliferation based on the
measurement of bromodeoxyuridine (BrdU) incorporation
during DNA synthesis, and is a non-radioactive alternative
to the [3H]-thymidine incorporation assay. Cells were grown in
96 well culture dishes (104 cells/well), incubated with C2- or
C6-ceramide for different time intervalls, and then labelled
with BrdU for a further 4 h. Incorporated BrdU was measured
colorimetrically.
2.5. Lipid extraction and ceramide quantitation
Sub-confluent Caco-2-cells in 30 mm-diameter dishes were
stimulated with increasing concentrations of resveratrol [50–
200 mmol/L] for 24 h. Lipids were extracted according to the
method established by Bligh and Dyer [17], and ceramide was
quantitated by mass-spectrometry as previously described
[18].
2.6. ODC-activity
The activity of the enzyme ODC was assayed with a radio-
metric technique in which the amount of 14CO2 liberated from
DL-[1-14C]ornithine (207.2_104 MBq/mol, Hartman Analytics
Amersham Pharmacia Biotech, Freiburg, Germany) was
estimated, as described earlier [13].
2.7. Transfection assay
The following plasmids were used for transfection: pcDNA3
(Invitrogen), as an empty vector for control transfection and
the plasmid pcDNA3-PPARgL468A/E471A, a dominant-nega-
tive doublemutant, that was kindly provided by VK Chatterjee
(Department of Medicine, University of Cambridge, Adden-
brooke’s Hospital, Cambridge, United Kingdom) [19]. These
constructs were transfected into subconfluent Caco-2 cells
with lipofectamine 2000 (Invitrogen). After 6 h the cells were
fed with fresh medium containing 10% FCS. Twenty-four
hours later the cells were fed with medium containing
Geneticine (G418) [400 mg/mL] and culture medium was
replaced twice a week. G418-resistant colonies were collected
and used for further analysis.
2.8. Statistics
The data are expressed as means  S.E. of at least three
independent experiments. Analysis of variance (ANOVA) was
performed when more than two groups were compared, and
when significant (p < 0.05), multiple comparisons were
performed with the Turkey test. A p < 0.05 was considered
to be significant.3. Results
3.1. Effects of resveratrol on ceramide synthesis
First we examined the effect of resveratrol [50–200 mmol/L] on
the intracellular ceramide concentrations of Caco-2 cells using
mass-spectometry. After 24 h of incubationwe could observe asignificant dose-dependent up-regulation of C16-ceramide
levels 6.5-fold at 200 mmol/L [***p < 0.001] (Fig. 1).
3.2. Effects of C2- and C6-ceramides on cell proliferation
and cell counts
Since natural ceramides are not permeant to cell membranes,
our study has been carried out by using short chain cell-
permeable analogs to determine the role of ceramides in this
signal transduction pathways. Caco-2 and HT-29-cells were
incubated with increasing concentrations of C2- and C6-
ceramides [1–40 mmol/L] for 24, 48 and 72 h. After each time
interval both cell proliferation ELISA (BrdU) and crystal violet
staining were performed. Both in Caco-2- and HT-29-cells a
significant time- and dose-dependent decrease in cell pro-
liferation and cell counts could bemeasured,wherebywe limit
our illustrations on the effects after 48 h (Fig. 2).
3.3. Effects of ceramides on ODC activity as well as on c-
myc and ODC protein expression
Resveratrol on the one hand induces intracellular ceramide
synthesis and on the other hand reduces the protein levels of
the protooncogenes c-myc and ODC [6]. To reveal a possible
coherency, we first measured the effects of C2- and C6-
ceramides [10–40 mmol/L] in Caco-2-cells (Fig. 3A and B) and
C2- [10–30 mmol/L] and C6- [1–10 mmol/L] ceramides in HT-29-
cells (Fig. 3C and D) on ODC activity after 24 h of treatment
which both caused a significant inhibition in dose-dependent
manner [***p < 0.001]. We further have done Western blot
analysis tomeasure effects on the protein levels of ODC and c-
myc after treatment with the C6-ceramide N-hexanoylsphin-
gosine [10–40 mmol/L]. And actually a dose-dependent
decreases both in c-myc (Fig. 4B) [**p < 0.001] and ODC
(Fig. 4D) [*p < 0.05] protein levels comparable to the resvera-
trol-induced effects [6] could be observed after 6 h of
incubation.
Fig. 2 – (A) Cell counts and (B) cell proliferation of Caco-2 cells 48 h after incubation without (control) or with C2-ceramide [10–
40 mmol/L] or C6-ceramide [10–40 mmol/L]. The ceramides lead to a conspicuous dose- and time-dependent reduction of cell
counts as well as an inhibition of cell proliferation. MeansW S.E., n = 3. (C) Cell counts and (D) cell proliferation of HT-29 cells
48 h after incubation without (control) or with C2-ceramide [10–30 mmol/L] or C6-ceramide [1–10 mmol/L]. The ceramides
again lead to a conspicuous dose- and time-dependent reduction of cell counts as well as an inhibition of cell proliferation.
MeansW S.E., n = 3; *p < 0.05; **p < 0.01; ***p < 0.001 vs. control.
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induced inhibition of ODC activity
Twomajor pathwaysmay contribute to intracellular ceramide
accumulation: namely the sphingomyelinase (SMase)-depen-
dent catabolism of sphingomyelin, as well as de novo synthesis
catalyzed through serine palmitoyltransferase. Hence, we
tested whether selective pharmacological inhibitors of these
two key enzymes were able to prevent resveratrol-induced
inhibition of ODC-activity in Caco-2- and HT-29-cells. While
co-incubationwith the SMase inhibitormanumycin [1 mmol/L]
causes no changes in resveratrol action, blockade of de novo
ceramide synthesis with the SPT-inhibitors L-cycloserine
[1 mmol/L] and myriocin [5 mmol/L] counteracted inhibitory
effects of resveratrol [100 mmol/L] on ODC-activity (Fig. 5). To
further verify the involvement of ceramide synthesis in
resveratrol-mediated effects we treated Caco-2 cells with
resveratrol [100 mmol/L] alone and in combination with L-
cycloserine andmeasured the protein levels of c-myc andODC
after 24 h of incubation. As already shown in earlier studies [6]
resveratrol leads to a significant decrease of both c-myc
[***p < 0.001] (Fig. 4A) and ODC [***p < 0.001] (Fig. 4C) protein
levels, which could be significantly reduced [*p < 0.05], when
ceramide de novo synthesis was suppressed.3.5. The effect of exogenous spermine on resveratrol-
induced reduction of cell counts
To determine whether the decrease in c-myc and ODC are the
cause of decreased growth rate or a result, we performed an
add-back experiment with exogenous spermine [50 mmol/L].
For this we treated Caco-2-cells with spermine [50 mmol/L],
resveratrol [50–100 mmol/L] and the combination of both and
measured the cell counts after 48 h of incubation (Fig. 6). As
spermine was able to counteract resveratrol-actions signifi-
cantly, we conclude that the observed reduction of cell counts
after resveratrol-treatment is due to a reduction of intracel-
lular polymine levels.
3.6. The role of PPARg in resveratrol-induced inhibition of
ODC activity
As previously shown [20] the activation of transcription factor
PPARg plays a crucial role in resveratrol-induced activation of
catabolic SSAT. So, we wanted to determine whether this
receptor is also involved in ODC inhibition. In accordance to
our recently published data,we now investigated the effects of
resveratrol [50–100 mmol/L] on ODC activity in Caco-2-wild-
type cells compared to Caco-2-cells transfectedwith either the
Fig. 3 – Influence of C2- and C6-ceramide on ODC activity in Caco-2- and HT-29-cells. Caco-2-cells were treated for 24 h with
increasing concentrations of (A) C2-ceramide [10–40 mmol/L] and (B) C6-ceramide [10–40 mmol/L], HT-29-cells with (C) C2-
ceramide [10–30 mmol/L] and (D) C6-ceramide [1–10 mmol/L]. ODC activity was determined by 14CO2-release from labelled
ornithine. Results (meansW S.E.; n = 4) are expressed in enzyme units (picomole of released CO2) per milligram cellular
protein per hour. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control.
b i o c h em i c a l p h a rma c o l o g y 7 4 ( 2 0 0 7 ) 2 8 1 – 2 8 9 285empty vector or a dominant-negative PPARgmutant after 24 h.
But in contrast to SSAT activation PPARg seems not to be
essential for resveratrol-induced ODC inhibition as no
differences could be observed, when PPARg mediated func-
tions are suppressed (Fig. 7).4. Discussion
Colorectal cancer is a major public health concern in all
developed countries. Despite decades of advances in the
treatment and prevention of colorectal cancer, it remains the
second most common cause of cancer death [21]. Hence,
interest in the concept and practice of chemoprevention
as an approach to arrest or reverse carcinogenesis at its
earliest stages has increased greatly in the past few years
[22]. Therefore, dietary polyphenols are of great interest
due to their antioxidative and anticarcinogenic activities.
Resveratrol, present in red wines, peanuts and grapes,
exhibits multiple chemopreventive effects comprising
inhibition of cell growth [23,24] and angiogenesis [25]
as well as induction of apoptosis [26], whereby the under-
lying molecular mechanisms are only partly deciphered
[6,20].It is now well established that ceramides are important
second messengers for cell regulation which participate in
signal transduction by activating specific serine/threonine
kinases, or by stimulating protein phosphatases. An increase
in intracellular ceramide concentrations could be induced by
multiple exogenous agents comprising TNF-a, Fas ligand,
1a25-dihydroxyvitamin, chemotherapeutic agents, heat
stress and interleukin-1 [27,28]. Over the past few years there
has been an escalating interest in exploring the role of
ceramide and its metabolites in tissue physiology and
pathophysiology. Typically, strategies that elevate cellular
ceramide are being used for therapies aimed to arrest growth
or promote apoptosis [29,30]. Interestingly, we could show
that also the antiproliferative effects of resveratrol closely
correlate with a dramatic increase of endogenous ceramides.
Similar effects could be observed in ametastatic breast cancer
cell model, when ceramide levels increased 5- and 10-fold
after treatment with resveratrol 32 and 64 mmol/L, respec-
tively, in comparison with untreated cells [31]. Treatment
with C2- or C6-ceramide in turn, caused distinct growth
inhibition in our colorectal cancer cell model. Sala et al.
hypothesize that the phenolic moiety is critical for the
ceramide-associated growth-inhibitory effects of resveratrol
[32]. While the activation of mitogen-activated protein kinase
Fig. 4 – Western blot of c-myc (A) and ornithine decarboxylase protein (C) in Caco-2-cells after incubation with resveratrol
[100 mmol/L] and cycloserine [1 mmol/L] alone and in combination for 24 h. Western blot of c-myc (B) and ornithine
decarboxylase protein (D) in Caco-2 cells after incubation with increasing concentrations of C6-ceramide [10–40 mmol/L] for
6 h. A representative immunoblot of three independent experiments is shown. The graph presents the densitometric
analysis. MeansW S.E.; n = 3; Values not sharing a letter differ significantly; *p < 0.05, **p < 0.01.
b i o c h em i c a l p h a rma c o l o g y 7 4 ( 2 0 0 7 ) 2 8 1 – 2 8 9286p38 plays a crucial role in resveratrol-induced SSAT-activa-
tion [20], an involvement in ceramide-mediated actions is
discussed controversially [33–35] and requires further inves-
tigations.Nearly 70% of human colon cancers are associatedwith the
activation of proto-oncogene c-myc [36], a transcription factor
that directly regulates the expression of ornithine decarbox-
ylase (ODC) by binding to a specific CACGTG sequence in the
Fig. 5 – Effects of serine palmitoyltranferase inhibitors
cycloserine [1 mmol/L] and myriocin [5 mmol/L] and
sphingomyelinase-inhibitor manumycin [1 mmol/L] on
resveratrol-induced ODC inhibition in Caco-2- and HT-29-
cells after 24 h of incubation. Results (meansW S.E.; n = 4)
are expressed in enzyme units (picomole of released CO2)
per milligram cellular protein per hour. # not significant,
*p < 0.05 **p < 0.01 vs. control.
Fig. 7 – Activity of ornithine decarboxylase (ODC) in Caco-2-
wildtype cells in comparison to transfected Caco-2 empty
vector- and Caco-2-dnPPARg cells after incubation with
resveratrol [50–100 mmol/L] for 24 h. MeansW S.E.; n = 4;
**p < 0.01 vs. control.
b i o c h em i c a l p h a rma c o l o g y 7 4 ( 2 0 0 7 ) 2 8 1 – 2 8 9 287gene promoter [37]. ODC in turn has long been known as a
marker of carcinogenesis and tumor progression [38]. Based on
our earlier findings that resveratrol regulates the expression of
both c-myc and ODC genes [6], together with the results from
Flamigni et al. [39] who demonstrated a reduction of c-mycFig. 6 – Cell counts of Caco-2 cells 48 h after incubation with
spermine [50 mmol/L], resveratrol [50–100 mmol/L] and the
combination of both. Spermine significantly counteracts
Resveratrol-induced reduction of cell counts. MeansW S.E.;
n = 2. Values not sharing a letter differ significantly.and ODC expression in leukemia cells after ceramide-treat-
ment, we tried to identify a possible involvement of ceramide
de novo biosynthesis in the regulatory pathway in colorectal
cancer cells. We measured c-myc as well as ODC expression
after treatment with N-hexanoylsphingosine (C6-ceramide)
and with resveratrol in combination with the specific serine
palmitoyltransferase inhibitor L-cycloserine. While N-hexa-
noylsphingosine led to an obvious decrease of both c-myc and
ODC protein levels, L-cyloserine but not sphingomyelinase-
inhibitor manumycin conspicuously counteracted the inhibi-
tory effects of resveratrol. Similar effects could be obtained in
ODC activity.
Peroxisome-proliferator-activated receptors (PPARs) are
ligand-activated transcription factors that heterodimerize
with the RXRs and bind to peroxisomal proliferator response
elements in the promoter region of multiple target genes [40–
43]. Three PPAR isoforms have been described (a, b and g).
Several epidemiologic and in vitro studies suggest, that
activation of PPARg is associated with the prevention of colon
cancer [43,44]. In a recently published study we could show,
that activation of PPARg is essentiell for resveratrol-induced
activation of SSAT, the catabolic enzyme of polyamine
metabolism [20]. Hence, we were interested, whether PPARg
activation plays another crucial role in resveratrol-induced
ODC inhibition. To determine PPARg-mediated functions we
transfected a dominant-negative mutant in Caco-2 cells,
which retains ligand and DNA binding, but exhibits markedly
reduced transactivation due to impaired coactivator recruit-
ment [19]. But in contrast to SSAT induction, PPARg activation
seems not to be critical for resveratrol-mediated ODC
inhibition, as no differences in resveratrol-actions could be
observed, when PPARg mediated functions are suppressed
(Fig. 7).
The identification of increased polyamine concentrations
in a variety of cancer tissues has led to the design and
development of inhibitors of polyamine metabolism as a new
b i o c h em i c a l p h a rma c o l o g y 7 4 ( 2 0 0 7 ) 2 8 1 – 2 8 9288strategy for therapeutic or preventative interventions. The
best-known inhibitor of polyamine biosynthesis is alpha-
difluoromethylornithine (DFMO), a specific inhibitor of
ornithine decarboxylase [45]. Even though triggering promis-
ing effects in vitro, DFMO has been less successful in cancer
therapy, resulting in cytostatic rather than cytotoxic effects in
vivo [46]. Althoughmuch emphasis in the past has been on the
biosynthetic pathway of polyamine metabolism, considerable
interest has recently been generated with regard to the
catabolic pathways, maintaining a properly balanced ratio of
polyamines in cells [47]. This suggestion may well explain the
increased efficacy of combined chemopreventive therapywith
non-steroidal anti-inflammatory drugs (NSAIDS) in animal
models, as this agents recently have been shown to induce
SSAT gene expression [48]. In this context resveratrol could
show great therapeutic potential in the chemoprevention and
treatment of colorectal cancers, by simultanously leading to
SSAT activation as well as ODC inhibition.
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ABSTRACT   
 
Previous studies could demonstrate that ursolic acid (UA), a pentacyclic triterpene found in 
berries and plants has antiproliferative as well as proapoptotic activities on cancer cells. The 
objective of this study was to elucidate the underlying molecular mechanisms of these 
chemopreventive effects. 
We could show, that treatment with UA leads to a significant time- and dose-dependent cell 
growth inhibition of colorectal cancer cells, coincident with the upregulation of the cell cycle 
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regulators cyclin E, p21WAF1/Cip1 and p27Kip1. In addition, UA significantly induces apoptosis, 
which is mediated by an increase of BAX/Bcl-2-protein-ratio as well as an upregulation of 
TRAIL protein which meets in an induction of caspase-3 activity. Furthermore, we could 
show that UA leads to a PPARγ-dependent induction of spermidine/spermine 
acetyltransferase (SSAT), a key enzyme of polyamine metabolism, which is associated with 
catabolism of intracellular polyamines and subsequent apoptotic responses. 
In conclusion, the observed reduction of cell growth of colon cancer cell lines after treatment 
with ursolic acid presumably results from a large increase in the number of apoptotic cells. 
The induction of the catabolic enzyme SSAT via PPARγ-dependent mechanisms therby 
seems to present the major molecular target in the induction of programmed cell death.  
 
 
  
 2
INTRODUCTION 
Ursolic acid is a pentacyclic triterpenoid compound which naturally occurs in a large number 
of berries, medicinal herbs and other plants. It was identified as the major biological active 
incredient in a large number of plants which are used in traditional east asian folk medicine as 
drugs exhibiting hepatoprotective, antiinflammatory and anti-tumor effects (for review see 1). 
Additionally, chemopreventive effects could be demonstrated in several cancer models 
comprising inhibition of proliferation as well as induction of apoptosis 2-4.  
Cell division relies on the activation of cyclins, which bind to cyclin-dependent kinases 
(CDKs) to induce cell-cycle progression towards S phase and later to initiate mitosis. Since 
uncontrolled cyclin-dependent kinase activity is often the cause of human cancer, their 
function is tightly regulated by cell-cycle inhibitors such as the p21WAF1/Cip1 and p27Kip1 
proteins 5. They have been described to regulate the G1-S transition by interacting with 
specific cyclin/cyclin dependent kinase complexes, and have also been shown to mediate 
growth arrest when overexpressed in the cell.  
Apoptosis or programmed cell death is defined as an active physiologic process of cellular 
self-destruction, with specific morphologic and biochemical changes in the nucleus and 
cytoplasm 6. The signaling event leading to apoptosis can be divided into two distinct 
pathways, namely the intrinsic and extrinsic pathway. Engagement of the intrinsic pathway 
results in altered mitochondrial membrane permeability and the release of pro-apoptotic 
factors including cytochrome c, caspase-9 and second mitochondria-derived activator of 
caspases (Smac)/DIABLO into the cytosol. Cytochrome c binds to apoptosis-inducing factor-
1 (Apaf1) and procaspase-9 to form the “apoptosome”, which leads to activation of caspase-9 
and subsequently caspase-3, resulting in apoptosis 7. A second caspase-independent pathway 
is characterized by the leakage of apoptosis-inducing factor AIF from mitochondria, resulting 
in direct chromatin condensation and DNA fragmentation 8. The extrinsic pathway is 
characterized by ligand fixation to death receptors present on the cell surface. These death 
receptors are members of the TNF receptor gene superfamily, which share similar, cysteine 
rich extracellular domains 9. Ligation of death receptors results in recruitment of adapter 
molecules such as FADD, which in turn recruits procaspase-8 to form the death inducing-
signaling complex (DISC) 10. DISC releases caspase-8, which activates caspase-3 11.  
Little is known about the underlying molecular mechanisms of ursolic acid related effects on 
cell proliferation and apoptosis in colorectal cancers. Thus the major aim of this study was to 
analyze modulatory effects on cell cycle regulating proteins as well as pro- and anti-apoptotic 
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factors and to further characterize signal transduction pathways leading to this 
chemopreventive actions. 
 
MATERIALS AND METHODS 
 
Cell culture. Caco-2 cells of passages 20-30 were kept in Dulbecco´s modified eagle medium 
(DMEM), supplemented with 10% fetal calf serum (FCS), 1% penicillin/streptomycin, 1% 
sodium pyruvate and 1% nonessential amino acids. HCT-116 and HT-29 cells of passages 17-
30 were cultured in McCoy’s 5A supplemented with 10% FCS and 1% 
penicillin/streptomycin. Both cell lines were maintained at 37°C in an atmosphere of 95% air 
and 5% CO2. The cells were passaged weekly using Dulbecco´s PBS containing 0.25 % 
trypsin and 1 % EDTA. The medium was changed three times per week. Cells were screened 
for possible contamination with mycoplasma at monthly intervals. For experiments, the cells 
were seeded onto plastic cell culture wells in serum-containing medium and allowed to attach 
for 24h. For the SSAT activity assay the cells were synchronized in medium containing 1% 
FCS 24h before treatment. Ursolic acid, Fetal calf serum (FCS) and dimethylsulfoxide 
(DMSO) were obtained from Sigma-Aldrich (St. Louis, MO), Dulbecco’s modified Eagle’s 
medium (DMEM) and Geneticin (G418) from Gibco/Invitrogen (Carlsbad, CA); sodium 
pyruvate solution, glutamine, penicillin and streptomycin stock solutions from PAA 
Laboratories GmbH (Ontario, Canada); Lipofectamine™ 2000 from Invitrogen (Carlsbad, 
CA).  
 
Cell Counts 
Cells were suspended and cultured on 96-well dishes at a density of 104/well (0.28 cm2). 
Treatment started 24h after plating. At given time points following treatment cell numbers 
was assessed by crystal violet staining. Medium was removed from the plates and cells were 
fixed with 5% formaldehyde for 5 min. After washing with PBS cells were stained with 0.5% 
crystal violet for 10 min, washed again with PBS and unstained with 33% acetoic acid. 
Absorption, which correlates with the cell number, was measured at 620 nm.  
 
Cell Proliferation 
The effects of  ursolic acid on DNA synthesis of cells were assessed using an cell 
proliferation ELISA kit (Roche Diagnostics, Mannheim, Germany). This assay is a 
colorimetric immunoassay for quantification of cell proliferation based on the measurement of 
bromodeoxyuridine (BrdU) incorporation during DNA synthesis, and is a non-radioactive 
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alternative to the [3H]-thymidine incorporation assay. Cells were grown in 96-well culture 
dishes (104 cells/well), incubated with ursolic acid for different time intervalls, and then 
labelled with BrdU for a further 4 hours. Incorporated BrdU was measured colorimetrically. 
 
SDS-polyacrylamide gel electrophoresis and immunoblot analysis 
 
Caco-2 cells were seeded in 80 cm2 flasks; 24h after plating, cells were incubated with 
substances for different time intervals. Western blot analysis using total protein extracts from 
cultured cells was performed as previously described 12. Protein was quantified with the Bio-
Rad (Bio-RAD Laboratories, Munich, Germany) protein colorimetric assay. Reprobing of 
blots for expression of β-actin was done routinely. Antibodies for p21WAF1/CIP1, p27KIP1, 
Cyclin E and BAX were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
Bcl-2 was purchased from Cell Signaling (Danvers, MO) and anti-TRAIL from Cayman 
Chemicals (Ann Arbor, MI). For quantitative analysis, bands were detected and evaluated 
densitometrically by ProViDoc system (Desaga, Wiesloch, Germany), normalized for the 
density of β-actin.  
 
Cell death detection assay 
To determine and quantify the induction of apoptosis by ursolic acid in colon cancer cells, 
cytoplasmic histone-associated DNA fragments were measured using a commercially 
available Cell Death Detection ELISA kit (Roche Diagnostics, Mannheim, Germany). 24h 
after treatment with the mentioned substances, one µg of cell lysate was used for the ELISA 
procedure, following the manufacturer’s instructions. DNA fragmentation was quantified 
photometrically at 405 nm.  
 
Caspase-3-Activity assay 
Activity of caspase 3 was determined using a fluorometric immunosorbent enzyme assay 
(Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s instructions. 
Briefly, cells grown in 6-well plates were incubated with increasing concentrations of ursolic 
acid for 24 h. Cells were washed with ice-cold PBS harvested in lysis buffer and centrifuged 
at 4°C for 2 minutes at 13000g. Caspase 3 from cellular lysates is captured by a monoclonal 
antibody on a coated microtiter plate. Following a washing step, subtrate is added that is 
cleaved proportionally to the amount of activated caspase 3. Due to proteolytic cleavage of 
the substrate, free fluorescent 7-amido-4-trifluoromethyl-coumarin (AFC) is generated. 
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Fluorescence was measured (excitation/emission, 430/535 nm) with the fluorescence 
microplate reader Tecan SpectraFluor PLUS. 
 
SSAT-Activity 
Cells were washed twice with cold homogenizing buffer (10mM Tris/HCl, pH 7.5, 2.5 mM 
DTT, 1mM EDTA), harvested by scraping, disrupted by sonification and centrifuged at 
15.000 g at 4°C for 15 min. Sixty microlitre aliquots of the supernatant  were incubated with 
0.3 µmol/L spermidine, 10 µmol/L Tris/HCl (pH 7.8), and 3,7 kBeq [acetyl-14C]CoA 
(Hartman Analytic GmbH, Braunschweig, Germany) at 37°C for 10 min. The reaction was 
terminated by chilling and the addition of 20 µl of 1M NH2OH. Subsequently, samples were 
centrifuged at 15.000 g for 5 min. Thirty microlitres of the supernatant were spotted onto a 
Whatman P81 paper disc (2.4 cm in diameter). The paper disc was washed with aqua dest. 
and ethanol on a filter, dried and transferred to a vial containing 3 ml of scintillation cocktail 
(Packard Biosciences, Groningen, The Netherlands). Radioactivity was measured in a liquid 
scintillation counter (Packard Instruments, Meriden, CT). Controls included samples for 
measurement of non-enzymatic incorporation of [acetyl-14C]CoA into monoacetlyspermidine. 
For all treatments tested the assay was repeated without addition of spermidine, to estimate 
unspecific acetylation by other enzymes than SSAT. These values were subtracted from the 
results obtained from the SSAT-activity measurements.  
 
Transfection assay 
The following plasmids were used for transfection: pcDNA3 (Invitrogen, Carlsbad, CA), as 
an empty vector for control transfection and the plasmid pcDNA3-PPARγL468A/E471A, a 
dominant-negative double mutant, that was kindly provided by VK Chatterjee (Department of 
Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, United Kingdom) 
13. These constructs were transfected into subconfluent Caco-2 cells with lipofectamine 2000 
(Invitrogen, Carlsbad, CA). After 6 h the cells were fed with fresh medium containing 10% 
FCS. G418 (400 µg/ml) and culture medium containing 10 % FCS. 24 hours later the cells 
were fed with medium containing G418 (400 µg/ml) and culture medium was replaced twice 
a week. G418-resistant colonies were collected and used for further analysis. 
 
Statistics 
The data are expressed as means ± SE of  at least three independent experiments. Analysis of 
variance (ANOVA) was performed when more than two groups were compared, and when 
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significant, multiple comparisons were performed with the Turkey test. A p value < 0.05 was 
considered to be significant. 
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RESULTS 
 
Effects of ursolic acid on cell growth of colorectal cancer cell lines 
Caco-2 [10-30 µmol/L], HCT-116 [5-15 µmol/L] and HT29 [5-15 µmol/L] cells were 
incubated with increasing concentrations of ursolic acid for 24 h, 48 h and 72 h. After each 
time interval both cell proliferation ELISA (BrdU) and crystal violet staining were performed. 
While not effective in Caco-2 cells after 24h of incubation ursolic acid leads to significant 
time- and dose-dependent decrease in cell counts (***p<0.001) as well as to a significant 
inhibition of cell proliferation (***p<0.001) in all cell lines after 48h at the latest. (Figures 
1A-D)  
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 Effect of ursolic acid on cell cycle regulating proteins 
To decipher the molecular mechanisms leading to cell growth inhibition we started to measure 
the expression status of several cell cycle regulating proteins (Figure 2), whereby the most 
prominent effects could be observed with the cell cycle inhibitors p21WAF1/Cip1 and p27Kip1. 
While ursolic acid [10-30 µmol/L] leads to a significant dose-dependent increase of p21 
WAF1/Cip1 protein levels already after 24h of incubation (~ 30% at 20 µmol/L, *p<0.05), an 
increase of p27 Kip1 levels could not be observed until 48h of treatment (~ 40% at 20 µmol/L, 
*p<0.05). Another interesting change could be detected in the expression levels of cyclin E, 
which is essential for progression through the G1-phase of the cell cycle and for initiation of 
DNA replication by interacting with and activating its catalytic partner, the cyclin dependend 
kinase 2 and therefore can be considered as a promotor of cell replication and proliferation. In 
contrast to our expectations, we could observe a significant dose-dependend increase in the 
protein levels of  cyclin E in Caco-2 cells after 24h of incubation with ursolic acid [10-30 
µmol/L] (~ 40% at 20 µmol/L, *p<0,05).  
 
Figure 2 
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 Induction of apoptosis by ursolic acid  
To evaluate a possible influence of apoptosis induction on the cell growth inhibition of Caco-
2, HCT-116 and HT-29 cells, we investigated DNA fragmentation as a marker of 
programmed cell death. Thereby, ursolic acid [5-30 µmol/L] causes a significant dose-
dependent increase of DNA-fragments after 24h of incubation [***p<0,001 vs. control at 
15/30 µmol/L in all cell lines] (Figure 3). Additionally, we measured caspase-3-activity in 
Caco-2 cells at the same point of time as a further marker of apoptotic actions. Again, ursolic 
acid seems to exhibit pro-apoptotic properties, as we could also observe a significant dose-
dependent increase of caspase-3-activity in Caco-2-cells [***p<0.001 vs. control] (Figure 4).  
 
Figure 3 
 
Figure 4 
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 Expression of apoptosis regulating proteins 
To specify the underlying molecular mechanisms leading to apoptosis after incubation with 
ursolic acid, we examined several apoptosis regulating proteins in Caco-2 cells by Western 
blot analysis. To analyse the effects on the intrinsic pathway we have chosen members of the 
Bcl-2 family of proteins, which are known to regulate membrane permeability and 
cytochrome c release from mitochondria. While ursolic acid [10-30 µmol/L] leads to an 
upregulation of proapoptotic BAX protein levels (up to ~20%), the expression of the 
antiapoptotic Bcl-2 was diminished after 24h of incubation (about ~40%). This results in a 
significant increase of the BAX/Bcl-2 protein ratio up to 60% (***p<0.001 at 30 µmol/L) 
(Figure 5A) which is generally known to trigger apoptosis 14,15. We further measured protein 
levels of TRAIL an immunological inducer of extrinsic mechanisms leading to programmed 
cell death. This ligand, binding to specific death receptors on the cell surface, was also 
significantly upregulated after 24h of incubation with ursolic acid [10-30 µmol/l] in a dose-
dependent manner (*p<0.05 at 30 µmol/L) (Figure 5B). 
 
Figure 5 
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 SSAT activation by ursolic acid 
Next we examined the effects of ursolic acid [20-30 µmol/L] on SSAT activity in Caco-2-
wildtype cells compared to Caco-2-cells transfected with either an empty vector or a dominant 
negative PPARγ mutant to investigate effects mediated by PPARγ. Ursolic acid  leads to a 
significant increase of SSAT activity [***p<0,001 vs. control at 30 µmol/L] in Caco-2-
wildtype cells after 24 h of incubation. In Caco-2-empty vector cells ursolic acid also 
significantly increases SSAT-activity [***p<0,001 vs. control at 30 µmol/L], whereas no 
effects could be observed when PPARγ mediated functions are suppressed in Caco-2-
dnPPARγ mutant cells (Fig 6).  
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 DISCUSSION 
Interest in the concept and practice of chemoprevention as an approach for the control of 
cancer has increased greatly in the past few years 16. Multiple natural agents have been shown 
to be effective for blocking carcinogenesis in certain human cancers and animal models. 
Using non-toxic chemical substances therefore is regarded as a promising alternative strategy 
to therapy for control of human cancers. The observed anti-carcinogenic effects may be due to 
blocking effects on the carcinogenesis stages of initiation, promotion, or progression 17,18. 
However, the precise underlying molecular mechanisms remain largely unknown. The aim of 
our study was to characterize chemopreventive effects of ursolic acid in a cell culture model 
of colorectal cancer. Attempts to show favourable effects in vitro have let to the identification 
of multiple direct targets for this compound. UA blocked cell cycle progression in the G1 
phase for example was shown to be associated with a marked decrease in the protein 
expression of cyclins and their activating partners the cyclin-dependent kinases 19-22 and with 
a concomitant induction of p21WAF1/Cip1 in miscellaneous cancer cell lines 23-25. Unfortunately, 
little reseach was done in colon cancer cells thereby mainly focusing apoptotic mechanisms 
26,27. After detecting potent cell growth inhibitory properties of ursolic acid we started to 
measure the expression status of several cell cycle regulating proteins, wherby the most 
prominent effects could be observed in the upregulation of cell cycle inhibitors p21WAF1/Cip1 
and p27Kip1. Contrary to expectations incubation with Ursolic acid also leads to a conspicious 
increase of cell cycle progressor cyclin E, which is however consistent with earlier findings 
by Wolter et al. 28 and Schneider et al. 29, which could show the same effects after treatment 
with the polyphenol resveratrol and take this as a result of a cell cycle arrest in the S-phase. 
However, cell cycle analysis of ursolic acid treated cells presents a predominant arrest in the 
G1 phase 30,31. These controversial results will deserve further investigations. Moreover, there 
are several lines of evidence, that the induction of cyclin E by genotoxic stress, such as 
ionizing radiation 32 or chemotherapeutic agents 33 could play a functional role in the initiation 
phase of apoptosis in malignant cells lines, in addition to its reported key regulatory role in 
the control of the G1 to S-phase transition and the initiation of DNA replication 34. Normally, 
the intracellular level and activities of p27Kip1 and cyclin E correlate negatively as there exist 
interdependence regulatory mechanisms. Simultaneous accumulations in both p27Kip1 and 
cyclin E are known to be characteristic phenotypes in cells derived from mice lacking S-phase 
kinase associated protein 2 (Skp2) 35 suggesting a possible involvement of protooncogene 
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Skp2 in the regulation of p27Kip1 and cyclin E, which might provide a target of ursolic acid 
mediated actions.  
Two major apoptosis pathways have been identified, the death receptor or extrinsic pathway 
and the mitochondrial or intrinsic pathway. The mitochondrial pathway is regulated by 
members of the bcl-2 protein family, which can be divided in pro- and anti-apoptotic groups. 
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the 
TNF family of cytokines, which can induce apoptotic cell death by engaging the death 
receptors DR4 and DR5, while sparing most normal cells 36. In certain tumor cell lines, 
TRAIL protein expression could be induced by chemopreventive agents resulting in TRAIL-
mediated apoptosis in an autocrine or paracrine manner 37-39. This suggests that endogenously 
expressed TRAIL, which we could also observe in our colon cancer model after ursolic acid 
treatment, may be at least partly responsible for the observed chemopreventive effects. The 
targeting of pro- and anti-apoptotic members of the Bcl-2 family of proteins, is the focus of 
efforts to modulate the intrinsic pathway of apoptosis and effect tumor death 40,41. While 
ursolic acid leads to an upregulation of proapototic BAX protein levels, the expression of the 
antiapoptotic Bcl-2 was diminished after 24h of incubation. This results in a significant 
increase of the BAX/Bcl-2 protein ratio which is generally known to trigger apoptosis 42,43. 
Taken together ursolic acid seems to lead to an activation both of extrinsic and intrinsic 
signaling pathways both resulting in Caspase-3 activation, followed by DNA fragmentation 
and programmed cell death. 
Ornithine-derived polyamines (putrescine, spermidine, and spermine) are biogenic organic 
polycations that are present in all living cells. They have pleiotropic effects, with a well-
described role as major metabolic regulators of cell proliferation and cell death balance 44. 
Intracellular levels of polyamines must be maintained within narrow limits, as a decrease is 
related to cell growth inhibition, whereas an excess appears to be toxic 45. A correlation 
between polyamines and cancer have been extensively studied for decades, pointing out the  
inhibition of polyamine biosynthetic enzymes ornithinedecarboxylase and s-
adenosylmethioninedecarboxylase or activation of catabolic enzyme spermidine/spermine 
acetyltransferase (SSAT) as a potential chemopreventive strategy 46-48. An association 
between SSAT induction followed by catabolism of the ubiquitous intracellular polyamines 
and subsequent apoptotic responses was first reported by Ha et al. 49. Furthermore, Chen et al. 
could demonstrate that selective interference of polyamine-analogue induced SSAT prevents 
apoptotic signaling and apoptosis in human melanoma cells 50. Much on the focus on SSAT 
has been on the functional level, but the regulation of SSAT gene expression has also been a 
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subject of recent investigations. Several transcription factors have been shown to activate 
SSAT expression. One regulatory pathway is the peroxisome proliferator (PPARs)-dependent 
pathway. These ligand-inducible transcription factors belong to the nuclear hormone receptor 
superfamily and occur in three different isotypes termed α, β and γ 51,52. We could show that 
PPARγ is essential for SSAT-activation mediated by ursolic acid, which is in accordance with 
our recently published data, presenting the same effects after treatment with the polyphenol 
resveratrol 53, possibly by binding to PPAR response elements, which could be identified on 
the promotor of the SSAT gene 54.  
 
 
CONCLUSION 
In conclusion, the observed reduction of cell growth of colon cancer cell lines after treatment 
with ursolic acid presumably results from a large increase in the number of apoptotic cells. 
The modulation of the polyamine metabolism, especially the induction of the catabolic 
enzyme SSAT via PPARγ-dependent mechanisms thereby seems to present the major 
molecular target in the induction of programmed cell death.  
Therefore, providing potent chemopreventive activities, phytochemicals like ursolic acid 
could in theory possibly serve as alternatives to chemically designed antineoplastic agents, as 
constituents of therapeutic drug combinations in advanced disease, or as adjuvant treatments. 
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FIGURE LEGENDS 
 
Fig 1. Cell counts and cell proliferation of colorectal cancer cell lines after incubation without 
(control) or with ursolic acid (UA). UA leads to a conspicuous time (24-72h) dependent 
decrease in cell counts (A) and to an inhibition of cell proliferation (B) of Caco-2-[30 
µmol/L], HCT-116-[15 µmol/L]  and HT29-cells [15 µmol/L]. After 72h of incubation, also a 
dose-dependent reduction of cell counts (C) as well as cell proliferation (D) could be observed 
in the tested cell lines (Caco-2 [10-30 µmol/L, HCT-116 and HT29 [5-15 µmol/L].  Means ± 
SE, n = 3; *p<0.05, **p<0.01, ***p<0.001. 
 
Fig 2. Expression of cell-cycle regulating proteins after ursolic acid treatment of Caco-2 cells.  
Ursolic acid [10-30 µmol/L] leads to a dose-dependent protein increase of cell cycle inhibitor 
p21WAF1/Cip1 and Cyclin E after 24h of incubation. An up-regulation of p27Kip1 protein could 
be observed after 48h of incubation.  For all proteins, a representative immunoblot of three 
independent experiments is shown.  Means ± SE; n=3  
 
Fig 3. (A) DNA-Fragmentation in colorectal cancer cells. 
Ursolic acid leads to a significant dose-dependent induction of apoptosis in Caco-2-[10-30 
µmol/L], HCT-116-[5-15 µmol] and HT29-cells [5-15 µmol/L] after 24h of incubation. 
Means ± SE; **p<0.01; ***<0.001.  
 
Fig. 4. Caspase-3-Activity in Caco-2 cells 
Treatment with ursolic acid in increasing concentrations [10-30 µmol/L] significantly 
activates pro-apoptotic caspase-3 after 24h.  Means ± SE, n=3, ***p<0,001. 
 
Fig 5. Expression of apoptose-related proteins in Caco-2-cells. 
 (A) Western blot of BAX and Bcl-2 after incubation with ursolic acid [10-30 µmol/L] for 
24h. For both proteins, a representative immunoblot of three independent experiments is 
shown. The graph presents the densitometric analysis of the BAX/Bcl-2 ratio after 24h. (B) 
TRAIL protein after incubation with ursolic acid [10-30 µmol/L] for 24h. A representative 
immunoblot of three independent experiments is shown. The graph presents the densitometric 
analysis of the TRAIL/β-actin ratio. Means ± SE; n=3; *p<0.05. Means ± SE; n=3, # = not 
significant, **p<0.01, ***p<0.001 
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Fig. 6 Activity of spermine/spermidine acetyltransferase (SSAT) in Caco-2-wildtype cells in 
comparison  to transfected Caco-2 empty vector- and Caco-2-dnPPARγ cells.  
Ursolic acid [10-30 µmol/L] leads to a significant increase in SSAT-activity both in Caco-2-
wildtype- and Caco-2-empty vector-cells after 24h of incubation. But no effects could be 
observed, when PPARγ-mediated functions are suppressed. Means ± SE; n=4; Values not 
sharing a letter differ significantly. **p<0.01. 
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ABSTRACT Resveratrol (3,4,5-trihydroxy-trans-stilbene),
a phytoalexin found in grape skins, peanuts, and red wine,
has been reported to exhibit a wide range of biological and
pharmacological properties. It has been speculated that
dietary resveratrol may act as an antioxidant, promote ni-
tric oxide production, inhibit platelet aggregation, and in-
crease high-density lipoprotein cholesterol and thereby
serve as a cardioprotective agent (the so-called “French
paradox”). Recently, it was demonstrated that resveratrol
can function as a cancer chemopreventive agent, and there
has been a great deal of experimental effort directed to-
ward defining this effect. It has been shown that resveratrol
and some of its analogues interfere with signal transduc-
tion pathways. Thus the activities of various protein kinases
are inhibited, the expression of nuclear proto-oncogenes
declines, and the activity of ornithine decarboxylase (ODC)
is reduced. ODC, which catalyzes the rate-limiting step in
the biosynthesis of polyamines, is closely linked with cel-
lular proliferation and carcinogenesis. This review summa-
rizes the recent advances that have provided new insights
into the molecular mechanisms underlying the promising
properties of resveratrol focusing on the key role of the
polyamine metabolism in colorectal cancer cells. J. Nutr.
134: 3219–3222, 2004.
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Colorectal cancer is not only the third most frequent can-
cer in the world but also one of the most common human
malignancies in Western countries. It affects men and women
almost equally, with about 400,000 new cases in men and
380,000 in women annually. Almost 400,000 deaths from
colorectal cancer still occur worldwide every year. Conven-
tional chemotherapy has no consistent benefit in overall sur-
vival. However, in recent years, multidisciplinary research in
epidemiology, molecular biology, and laboratory animal model
studies contributed much to the understanding of the etiology
of colorectal cancer. More important, these studies enabled
the design of highly promising preventive strategies, which are
about to influence both the incidence and the prognosis in
patients with a high risk of developing this disease (1).
Equally promising, however, are the preliminary data sug-
gesting that various nutrients may act as chemopreventive
agents as well (2). Indeed, a wide array of phenolic substances,
particularly those present in dietary and medicinal plants,
have been reported to possess substantial anti-carcinogenic
activities.
Recently, we and others (3–7) reported that the plant
polyphenol resveratrol and its analogs have a potent chemo-
preventive effect in multiple carcinogenesis models both in
vivo and in vitro. Resveratrol (3,4,5-trihydroxystilbene, mo-
lecular weight  228.2) is a polyphenol that has been classi-
fied as a phytoalexin, because it is synthesized in spermato-
phytes in response to certain types of stress. It is the active
ingredient of the dried roots of Polygonum cuspidatum, which
has been known in traditional Asian medicine under the name
Ko-jo-kon (8,9). Resveratrol-containing foods include grapes
(10,11), wine (12), and peanuts (13,14). In grapes, especially
when infected with Botrytis cinerea, resveratrol is exclusively
synthesized in the grape skins, which contain 50–100 mg
resveratrol/g when they are fresh. Because the grape skins are
not fermented in the production process of white wines, only
red wines contain considerable amounts of resveratrol. It has
been proposed that resveratrol is at least in part responsible for
the beneficial effects of a moderate red wine consumption on
the development of cardiovasular diseases. Resveratrol inhib-
ited platelet aggregation (15), protected porcine low-density
lipoproteins against polyunsaturated fatty acid peroxidation
(16), and exerted vasorelaxing effects on endothelium-intact
aorta rings of rats (17).
Additionally, the inhibitory potency of resveratrol in vari-
ous stages of tumor development has attracted much attention
(3). This review will summarize our work on the mechanisms
and activity of resveratrol and its derivative, focusing on
polyamine metabolism as a possible target.
Polyamines and Colorectal Tumorgenesis. The naturally
occurring polyamines putrescine, spermidine, and spermine are
widespread in nature and they have been detected in all
eukaryotic cells studied. Tissue polyamine levels are increased
either by biosynthesis (generally from ornithine and methio-
nine) or by uptake from extracellular fluids. Conversely, excess
cellular polyamines are removed by catabolic reactions con-
verting spermine to spermidine via a N1-acetylspermine inter-
mediate and eventually to putrescine via a N1-acetylspermi-
dine intermediate. The acetyl polyamines, along with excess
putrescine and spermidine, can be excreted to the extracellular
fluid. Cellular polyamine homeostasis is maintained through
the concerted effort of feedback systems controlling polyamine
transport as well as the 3 key enzymes in polyamine metabo-
lism, namely the production of putrescine by ornithine decar-
1 Manuscript received 1 September 2004.
2 Supported by a graduate scholarship grant from the DFG to Sandra Ulrich
and by the Else-Kro¨ner Fresenius Foundation, Bad Homburg, Germany.
3 To whom correspondence should be addressed.
E-mail: j.stein@em.uni-frankfurt.de.
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boxylase (ODC),4 the synthesis of decarboxylated S-adenosyl-
L-methionine decarboxylase (SAMDC, AdoMet-DC), and the
acetylation of spermidine and spermine by spermindine/sperm-
ine N1-acetyltransferase (SSAT) (Fig. 1).
In colon cancer tissue the activities of polyamine-synthe-
sizing enzymes and polyamine content are increased 10- to
15-fold in comparison to normal colonic epithelium (18,19),
and polyamines have therefore been considered even as spe-
cific markers for neoplastic proliferation in the colon (20).
ODC activity and expression have been among the first bio-
markers of neoplastic proliferation: as early as 1984 it was
shown that ODC activity correlates with risk for neoplastic
transformation in patients with colonic adenomatous polyposis
(21). ODC activity correlates also with degree of dysplasia in
Barrett’s esophagus (22) and different stages of colonic carci-
nogenesis (23). ODC activity is essential for cell proliferation
and is required for progression into the S phase of the cell cycle
(24). Studies suggest that ODC can be defined as a proto-
oncogene (25) and overproduction of this enzyme results in
malignant transformation (25–27). More important, how-
ever, is that polyamine uptake is upregulated by various
mitogens and hormones, as well as by some known tumor
promoters (28–31). On the other hand, it has been dem-
onstrated that polyamines stimulated the transcription of
c-myc and c-fos (32).
Involvement of Ornithine Decarboxylase in Cancer
Prevention and Therapy by Resveratrol and Its
Analogs. As stated above, polyamines and their biosynthetic
enzyme ODC are intimately involved in carcinogenesis and
malignant growth. It is possible that the anticancer and the
chemopreventive activities of resveratrol and its analogs could
also be explained by inhibiting ODC/SAMDC and/or increas-
ing SSAT activity. To test this assumption, we and others
investigated the effect of resveratrol on polyamine metabo-
lism. TPA-induced ODC activity in mouse 308 cells was
inhibited by 48% when treated with 10 mol/L piceatannol,
whereas resveratrol had no inhibitory effect at this concentra-
tion (33). Schneider et al. (34) incubated Caco-2 colorectal
adenocarcinoma cells with 25 mol/L resveratrol and detected
decreased ODC activity (58% of the control value) after 24 h.
The inhibitory effect intensified after 48 h. A direct enzyme
inhibition of resveratrol on ODC activity was excluded. We
could demonstrate that the decreased ODC activity in Caco-2
cells was accompanied by decreased levels of ODC protein,
implicating either increased degradation by the 26S protea-
some pathway or impaired ODC synthesis. When mRNA
levels of the odc gene were determined, a reduction of the odc
mRNA became evident. c-Myc protein was quantified be-
cause it controls the odc promoter. c-Myc was diminished by
resveratrol treatment, demonstrating that decreased expres-
sion of the odc gene is responsible for the inhibition of ODC
activity. Piceatannol also exerts an inhibitory effect on
ODC activity, with decreased ODC and c-myc protein
levels and with decreased odc mRNA levels, although the
inhibitory effect of resveratrol was more potent (7).
Whereas Schneider et al. (34) did not observe significant
inhibition of SAMDC activity after treatment of Caco-2
cells with 30 mol/L resveratrol (44), we demonstrated
SAMDC inhibition when higher concentrations (50
mol/L) were used. SAMDC was also inhibited by piceat-
annol, but the inhibitory effect was less pronounced (7).
4 Abbreviations used: DFMO, difluoromethylornithine; MAPK, mitogen acti-
vated protein kinase; ODC, ornithine decarboxylase; PAO, polyamine oxidase;
SAMDC, S-adenosyl-L-methionine-decarboxylase; SSAT, spermidine/spermine-
N-1-acetyltransferase.
FIGURE 1 Regulation of intracel-
lular polyamine content in mammalian
cells [adapted from Ref. (51)].
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Polyamine-Catabolizing Enzymes [SSAT and Polyamine
Oxidase (PAO)] as Molecular Targets for Resveratrol
and Its Analogs. An early response of human tumor cells to
etoposide-induced apoptosis was an increase in PAO activity
(35), and increases in SSAT activity have been linked to
cytotoxicity in neoplastic cells (36). Cancer cells exposed to
polyamine analogs/inducers of SSAT arrest their growth in G1
and induce the p53-p21WAF1/CIP1-Rb pathway, ultimately un-
dergoing apoptosis (37). The induction of both SSAT and
PAO can produce an efficient system to generate locally high
concentrations of hydrogen peroxide that could effectively
induce a signaling pathway ultimately leading to cell death.
Both SSAT and PAO activities were found to be decreased in
human solid tumors (38). In this study both enzyme activities
correlated with prognosis—PAO in a negative manner and
SSAT in a positive manner—supporting the idea that poly-
amine catabolism, particularly oxidation, is linked to tumor
growth potential. All these facts, although intriguing, have
been studied only partially so far.
Resveratrol and to a lesser extent piceatannol potently
upregulated SSAT activity, indicating that these hydroxystil-
benes induce polyamine degradation. After 24 h of treatment
with resveratrol we observed increased intracellular putrescine
and N1-acetylspermidine concentrations, whereas the levels of
spermine and spermidine did not change significantly (7).
Schneider et al. (34) detected reduced levels of putrescine and
spermidine after 48 h of treatment with 25 mol/L resveratrol.
The resveratrol analogue cis-3,5,4trimethoxystilbene de-
creased ODC and SAMDC activities at a concentration of 0.3
mol/L with a concomitant reduction of putrescine concen-
trations after 24 h (39). c-Fos and c-jun are part of the
transcription factor complex AP-1, which can consist of dif-
ferent Fos or Jun family proteins. The individual combination
of these proteins seems to be responsible for the effect of the
transcription factor. Proliferation, differentiation, or apoptosis
can be the result of enhanced AP-1 binding activity. c-Fos is
implicated in the process of differentiation and programmed
cell death. Resveratrol treatment led to increased levels of
c-fos and c-Jun in Caco-2 cells. Only the DNA-binding activ-
ity of c-fos increased, whereas c-jun binding activity remained
unchanged (7). These results may be mediated by the in-
creased putrescine levels measured after 24 h, which were
caused by enhanced SSAT activity. Accumulation of intra-
cellular putrescine concentration induces c-fos (40).
It has been well established that growth factors (mitogens)
bind to specific receptors located on the cellular membrane.
The mitogen-receptor complexes then trigger a cascade of
events including the activation of Ras, which activates the
kinase Raf and suppresses expression of SSAT by inhibition of
peroxisome proliferator-activated receptor  (41). The activa-
tion of protein kinases is regarded to be the next step in signal
transduction. Mitogen activated protein kinases (MAPKs) are
phosphorylated by MAPK/extracellular signal regulated ki-
nases, which are, in turn, activated by Raf. MAPKs next
trigger the expression of the nuclear oncogenes myc, jun, and
fos (Fig. 2), which function as transcription factors, stimulat-
ing proliferation and the expression of the ODC gene (42,43).
Polyamines, which are formed by ODC, enhance the expres-
sion of protein kinases (44) and nuclear oncogenes (32).
Difluoromethylornithine (DFMO), which inhibits polyamine
synthesis, prevents the expression of protein kinases (44) and
nuclear oncogenes (32); resveratrol also inhibited MAPK ac-
tivity (45). The inhibitory effect of resveratrol on polyamine
metabolism in carcinoma cells is presumably mediated by a
different pathway. Diminished ODC activity is very likely
mediated by decreased c-myc protein levels as demonstrated in
Caco-2 cells, because c-myc regulates odc expression (7). c-
Myc expression is regulated by the transcription factor E2F1.
We and others have demonstrated that resveratrol treatment
leads to decreased retinoblastoma protein phosphorylation and
thus inactivation of E2F family members (4,46). These data
suggest that ODC inhibition could be a result of the cell cycle
inhibitory effect of resveratrol. Most studies concerning poly-
amine metabolism as a target for chemoprevention or cancer
treament have focused on inhibition of ODC. This approach
has not proved efficient under in vivo conditions, because
ODC inhibition led to an increased polyamine uptake from
food, which neutralized cytostatic effects of DFMO (27,47).
Results obtained from studies with novel polyamine analogs
have suggested that induction of SSAT is a more promising
approach to chemoprevention (48–50).
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Molecular mechanisms of the chemopreventive
effects of resveratrol and its analogs in
carcinogenesis
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Resveratrol (3,49,5-trihydroxy-trans-stilbene), a phytoalexin found in grape skins, peanuts, and red
wine, has been reported to exhibit a wide range of biological and pharmacological properties. It has
been speculated that dietary resveratrol could be an explanation for the so-called
,
French paradox’ as
it may act as an antioxidant, promote nitric oxide production, inhibit platelet aggregation, and
increase high-density lipoprotein cholesterol, and thereby serve as a cardioprotective agent. Recently,
it has been demonstrated that resveratrol can function as a cancer chemopreventive agent, and there
has been a great deal of experimental effort directed toward defining this effect. It has been shown
that resveratrol and some of its analogs interfere with signal transduction pathways, modulate cell
cycle-regulating proteins, and is a potent inducer of apoptosis in multiple carcinoma cell lines. This
review summarizes the recent advances that have provided new insights into the molecular mecha-
nisms underlying the promising properties of resveratrol.
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1 Introduction
In addition to cardiovascular diseases, cancer is one of the
leading causes of death worldwide. Each year, the Ameri-
can Cancer Society estimates the number of new cancer
cases and deaths expected in the United States in the current
year, and compiles the most recent data on cancer inci-
dence, mortality, and survival by using incidence data from
the National Cancer Institute (NCI) and mortality data from
the National Center for Health Statistics (NCHS). A total of
1368030 new cancer cases and 563700 deaths were
expected in the United States in 2004. The three leading
cancer types for the estimated new cancer cases are at first
cancers of the genital system, with 33% prostate cancers in
male and 32% breast cancers in female, followed by about
13% cancers of lung and bronchus. Colorectal cancer is the
third most common cancer. It affects both genders almost
equally, with about 401000 new cases in men annually and
381000 in women [1]. It is estimated that 394 000 deaths
from colorectal cancer still occur worldwide annually, and
colorectal cancer is the second commonest cause of death
from any cancer in men in the European Union [2]. Cancer
is caused by both external (tobacco, chemicals, radiation,
and infectious organisms) and internal factors (hormones,
mutations, and immune conditions). One of the major risk
factors is age as about 76% of cancers are diagnosed at age
55 and older. Other risk factors include smoking, alcohol
consumption, obesity, physical inactivity, a high-fat diet, as
well as inadequate intake of fruits and vegetables [1].
As conventional chemotherapy has no consistent benefit in
overall survival, attention is focusing on preventative strate-
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gies for multiple cancers [3–9]. Chemoprevention is
defined as the employment of drugs or natural compounds
to prevent malignant tumors [10]. Several epidemiological,
clinical, and experimental studies established nonsteroidal
anti-inflammatory drugs (NSAIDs) as promising cancer
chemopreventive agents [11]. Long-term use of aspirin and
other NSAIDs has been shown to reduce the risk of cancer
of the colon and other gastrointestinal organs as well as of
cancer of the breast, prostate, lung, and skin [12]. But also a
large number of natural compounds have been linked to a
possible decreased incidence of developing cancers [13–
15]. Among others there is a special focus on polyphenols
present in dietary and medicinal plants exhibiting anti-car-
cinogenic activities [16].
The plant polyphenol resveratrol (3,49,5-trihydroxy-trans-
stilbene; Fig. 1) has been classified as a phytoalexin,
because it is synthesized in spermatophytes in response to
certain types of stress, including injury, UV irradiation, or
fungal attack [17, 18]. It was first described as a component
in the root extracts of the weed Polygonum cuspidatum,
which has been known in traditional Asian medicine under
the name Ko-jo-kon [19]. Resveratrol naturally occurs in
grapes [20–22], wine [23], and peanuts [24–26]. An
important factor for resveratrol concentrations in wine is
the fermentation time in contact with grape skins because
resveratrol is produced by the skin but not by the fruit flesh
[27]. This explains the low concentrations in white wine
because the grape skins are not fermented in the production
process [23]. Resveratrol came to scientific attention as a
possible explanation for the “French paradox” as it has ben-
eficial effects on the development of cardiovascular dis-
eases [28]. It has been shown to inhibit platelet aggregation
and eicosanoid synthesis [29], to interfere with arachido-
nate metabolism [30], to exert strong inhibitory effects on
reactive oxygen species produced by human polymorpho-
nuclear leukocytes [31], to be an antioxidant more powerful
than vitamin E in preventing low-density lipoprotein (LDL)
oxidation [32], and to exert vasorelaxing effects on
endothelium-intact aorta rings of rats [33]. Further studies
could show that resveratrol is an agonist for the estrogen
receptor which may also be relevant to the reported cardio-
vascular benefits of drinking wine [34].
Additionally, we and others have examined that resveratrol
and its analogs (Fig. 1) exhibit multiple properties including
chemopreventive effects in several carcinogenesis models
both in vivo and in vitro [35–41]. Several signal transduc-
tion pathways have been examined to explain these effects.
One hypothesis is focusing on polyamine metabolism as a
possible target of resveratrol activity [42]. Because many
reviews regarding the preventive effect of resveratrol on
cardiovascular diseases have been published [43, 44], this
review will summarize our work on the mechanisms and
activity of resveratrol and its derivatives in carcinogenesis.
2 Resveratrol and its analogs in carcinogenic
in vivomodels
Oral administration of resveratrol inhibited tumor growth
of T241 fibrosarcoma in mice [45]. Rats inoculated with
Yoshida AH-130 hepatoma cells and treated with resvera-
trol (intraperitoneal injection) had a decreased tumor cell
number [46]. Lung cancer development in A/J mice
induced by benzo[a]pyrene and 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone was not inhibited by oral adminis-
tration of resveratrol [47, 48], whereas in Balb/c mice
resveratrol protects the lung from DNA damage and apop-
tosis caused by benzo[a]pyrene [49]. Additionally adminis-
tration of resveratrol per os reduced the number of aberrant
crypt foci in azoxymethane-induced tumorigenesis in the
rat colon and led to enhanced expression of the proapoptotic
protein Bax in these crypt foci [50]. In a 7,12-dimethyl-
benz[a]anthracene (DMBA)-induced mammary carcino-
genesis model in Sprague Dawley rats dietary administra-
tion of resveratrol had indeed no effects on body weight
gain and tumor volume but produced reductions in the inci-
dence, multiplicity, and extended latency period of tumor
development [51]. The mean survival time of mice inocu-
lated with 32Dp210 leukemia cells and treated with up to
80 mg resveratrol/kg body weight was not significantly
different from untreated controls, even though resveratrol
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Figure 1. Chemical structures of stilbene compounds cited in
this review. (I) 3,49,5-trihydroxystilbene (resveratrol); (II) trans-
resveratrol-3-O-D-glucoside (piceid); (III) cis-3,49,5-trimethoxy-
stilbene; (IV) 3,39,49,5-tetramethoxystilbene (piceatannol); (V)
3,5-dimethoxy-49-hydroxystilbene (pterostilbene); (VI)
29,3,49,5-tetramethoxystilbene; (VII) 2,3,49,5-tetrahydroxystil-
bene. Substituents are hydroxyl (OH) and methoxy (OCH3)
groups and O-b-D-glucose (OGlc).
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exerted antileukemic properties on 32Dp210 cells in vitro
[52]. In mice bearing highly metastatic Lewis lung carci-
noma tumors resveratrol inhibited the DNA synthesis of
tumor cells with an IC50 value of 6.8 lM. No effect could be
monitored on CD4+, CD8+, and natural killer cells, from
which the authors concluded that these cells are not respon-
sible for the effects of resveratrol on DNA synthesis [53].
The trans-resveratrol-3-O-D-glucoside (piceid) also inhib-
ited the proliferation of Lewis lung cancer cells, inoculated
into mice, but only at a concentration of 1000 lM. 2,3,5,49-
Tetrahydroxystilbene-2-O-D-glucoside was more effective
with an IC50 of 81 lM [54]. In addition, resveratrol treat-
ment of mice (40 mg/kg daily for 28 days) suppressed the
growth rate of subcutaneous neuroblastomas, resulting in
70% long-term survival [55]. The natural resveratrol analog
pterostilbene (3,5-dimethoxy-49-hydroxystilbene) inhibited
the development of mammary lesions in a mouse mammary
gland organ culture treated with 7,12-dimethylbenz[a]an-
thracene [56]. In ApcMin/+ mice, an animal model for famil-
iar adenomatous polyposis, the number of adenomas was
reduced by 70% (colons contained no polyps following
treatment) by a diet containing resveratrol. The intestinal
mucosa of treated mice was subjected to DNA array anal-
ysis. Downregulation of the mRNAs encoding for cyclin
D1, cyclin D2, DP-1, YB1, and RNA polymerase termina-
tion factor TTF-1 could be monitored along with an
increase of transforming growth factor (TGF)-b, thrombo-
poietin, glutamate receptor, mitogen-activated protein
kinase (MAPK), TSG101 tumor susceptibility protein, and
other targets [36]. In contrast to these results, resveratrol
did not inhibit tumorigenesis in ApcMin/+ mice in a study
conducted by Ziegler et al. [57], even though reduced PGE2
levels could be observed in tumor tissue. Also in 4T1 breast
cancer cells resveratrol had no effects on growth inhibition
in vivo, although it exhibits potent inhibitory effects in vitro
[58]. These controversial results may be due to metabolic
processes, as resveratrol is absorbed in the small intestine
as resveratrol glucuronide. Glucuronides of phenolic com-
pounds have been assumed to be rapidly excreted in vivo
and to be pharmacologically inactive [59].
3 Effects of resveratrol and its analogs
in vitro
3.1 Resveratrol andMAPKs
The MAPKs convert extracellular signals (e.g., growth fac-
tor signals) into intracellular events. Three kinase pathways
(extracellular signal-regulated kinase (ERK), p38, and
c-Jun kinase (JNK) have been identified, that follow the
same principle of phosphorylation and activation cascades.
Targets of the MAPK pathways are transcription factors
like activator protein (AP)-1, c-Myc, and Elk-1. Tumor
necrosis factor (TNF-a)-induced AP-1, JNK, and MEK
(MAPK kinase) activation were inhibited in U937 lym-
phoma cells by pretreatment with resveratrol [60]. Resvera-
trol inhibited phosphorylation of ERK1 and ERK2 induced
by fibroblast growth factor 2 (FGF-2) in bovine capillary
endothelial cells [45] and by human serum in liver myofi-
broblasts [61]. In the cervical squamous cancer cell line
HeLa, pretreatment with resveratrol inhibited phosphoryla-
tion of p38, ERK2, c-Src, and JNK and subsequently activa-
tion of AP-1 induced by UV irradiation. PMA-induced
ERK2 and c-Src phosphorylation were strongly inhibited
by resveratrol, wheras resveratrol had only a weak effect on
epidermal growth factor (EGF)-induced ERK2-activation
[62]. In undifferentiated SH-SY5Y neuroblastoma cells,
treatment with resveratrol led to increased ERK1 and
ERK2 phosphorylation. At a concentration of 50 lM and
higher ERK phosphorylation was inhibited. Resveratrol
treatment of SH-SY5Y cells caused to differentiate with
retinoic acid decreased ERK phosphorylation at first, but
then increased ERK phosphorylation markedly [63]. In por-
cine coronary arteries resveratrol inhibited ERK activation
and tyrosine phosphorylation in a concentration-dependent
manner. Pretreatment with resveratrol counteracted
endothelin-1-stimulated ERK activity and tyrosine phos-
phorylation [64]. In another report it is shown that growth-
inhibitory concentrations of the phytochemical resveratrol
suppress endothelial growth factor receptor (EGFR)-
dependent ERK1/2 activation pathways stimulated by EGF
and phorbol ester (12-O-tetradecanoyl phorbol 13-acetate,
TPA) in human AI PrCa PC-3 cells in vitro. These effects
are mediated by protein kinase C (PKC) inhibition by
resveratrol, the major cellular receptor for phorbol esters.
The results provide evidence that resveratrol may have
value as an adjuvant cancer therapeutic in advanced pros-
tate cancer [65].
Resveratrol inhibited the activity of recombinant PKC pre-
pared from sonicated vesicles induced by 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphoserine with an IC50 value of
30 lM [66]. Resveratrol inhibited the PMA-induced redis-
tribution of PKC from cytosol to membrane in mammary
epithelial cells [67] and the autophosphorylation of isolated
protein kinase D in a dose-dependent manner, whereas it
had only negligible effects on PKC isozyme autophosphor-
ylation [68].
The natural ocurring stilbene analog piceatannol (trans-
3,49,39,5-tetrahydroxystilbene), which shares most of the
structural moieties with resveratrol, was first identified as
an inhibitor of the tyrosine kinase activity of p72Syk and
p56Lck in lymphoid cells [69]. In addition, piceatannol inhi-
bits the tyrosine kinase activity of human placenta [70] and
the focal adhesion kinase and Src in thrombocytes [71]. In
MCF-7 human breast cancer cells cAMP levels increased
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after addition of resveratrol. This effect was demonstrated
to be dependent on protein kinase A and phospholipase A2
activities and independent of the estrogen receptor [72].
3.2 Cell cycle
Inhibition of cell cycle progression is a possible target for
chemopreventive agents like resveratrol. The cell cycle is
regulated by cyclins and cyclin-dependent kinases (Cdk),
which are primarily regulated by their expression levels and
by cell cycle-inhibiting proteins (p21Waf1/Cip1, p27Kip1, and
members of the INK family of proteins) (Fig. 2). The effect
of resveratrol on the cell cycle distribution of tumor cells
seems to focus on the S-phase. A cell cycle arrest in the S-
phase has been reported for different cell types [37, 73–
81], except from HepG2 cells in which a G1 phase arrest
could be observed [82]. An increased cyclin E and cyclin A
expression was observed in HL-60 leukemia cells [83],
U937 lymphoma cells [78], HCT-116, and Caco-2 colon
cancer cells [37]. Ragione et al. [83] identified inactivation
of Cdc2 by phosphorylation at tyrosine residue 15 as a pos-
sible pathway by which this S-phase arrest is mediated. A
concentration-dependent decrease of the p27Kip1 expression
level was observed in LNCaP, U937, and Caco-2 cells [37,
77, 78]. In bovine pulmonary artery endothelial cells [75],
HL-60 cells [83], A431 cells [80], and U937 cells [78]
resveratrol treatment led to an increased p21Waf1/Cip1 expres-
sion, whereas the protein level of the cell cycle inhibitor
was unmodified in Caco-2 cells [37] and decreased in
LNCaP cells [77] and neuroblastoma cells [55]. In the
human prostate carcinoma cell line the antiproliferative
effect of resveratrol was associated with the inhibition of D-
type cyclins and Cdk 4 expression, and the induction of
tumor suppressor p53 and Cdk inhibitor p21. Moreover, the
kinase activities of cyclin E and Cdk2 were inhibited by
resveratrol without alteration of their protein levels [84].
The retinoblastoma protein (pRb) sequesters the transcrip-
tion factor E2F in the cytosol. Phosphorylation of pRb pre-
vents binding of pRb to E2F which leads to the transloca-
tion of E2F into the nucleus. Dephosphorylation and thus
activation of the tumorsuppressor pRb was observed in
Caco-2 cells [37] and in A431 epidermoid carcinoma cells
after treatment with resveratrol. In A431 cells this effect
was accompanied by decreased protein levels of all E2F
family members (1–5) and their binding partners DP-1 and
DP-2 [85]. Resveratrol arrested the cell cycle of non-andro-
gen responsive prostate cancer cell lines in the S-phase, but
did not modify the cell cycle distribution of the androgen-
responsive cell line LNCaP [86]. Stivala et al. [87] demon-
strated that the cell cycle effects of resveratrol are depend-
ent on certain structural determinants. The trans-configura-
tion in combination with the hydroxy group in the 49-posi-
tion is essential for the effects of resveratrol on the cell
cycle.
Cell cycle regulation was also observed in a few in vivo
studies. In H22-bearing mice, resveratrol inhibited the
growth of transplantable liver cancer by decreasing the
expression of cyclin B and cdc2 protein [88]. In another
study, resveratrol downregulated UVB-induced expression
of Cdk2, 4, 6 and cyclin D1 and D2 in SKH-1 hairless
mouse skin, which was accompanied by an upregulated
UV-mediated increase in the expression of the Cdk inhibitor
WAF1/p21 and the tumor supressor protein p53 [89]. In
addition to the regulation of cell cycle proteins, the negative
effect of resveratrol on proliferation has in part been attrib-
uted to inhibition of ribonucleotide reductase and DNA
synthesis [90].
Piceatannol is also a cell cycle inhibitor that acts preferably
in the S-phase. It has been demonstrated to inhibit the
growth of Caco-2 and HCT-116 colon cancer cell lines. Fol-
lowing piceatannol treatment, the number of Caco-2 cells
in the S-phase increased and reduced levels of Cdk4, Cyclin
D1, Cyclin B1, and p27Kip1 were detected. At the same time
an increase in Cyclin E and Cyclin A expression could be
shown. Taken together, these effects were comparable to
those observed after treatment with resveratrol [38]. The
methylated resveratrol analog cis-3,5,49-trimethoxystilbene
(0.3 lM) induces accumulation of Caco-2 cells in the G2/M-
phase with a diminished G0/G1-phase population. These
effects were caused by depolymerization of the microtubule
network [91].
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Figure 2. Cell cycle and possible modulation by resveratrol.
The polyphenol resveratrol has been shown to inhibit the activ-
ity of cdc2 and cdk4. Additionally there is an accumulation of
cyclins E and A, accompagnied by a decrease of D-type
cyclins as well as an increase of p21 expression. Furthermore,
resveratrol promotes dephosphorylation and thus activation of
the tumor suppressor pRb. These activities contribute to the
ability of resveratrol to inhibit cell progression at S-phase.
S. Ulrich et al. Mol. Nutr. Food Res. 2005, 49, 452–461
3.3 Apoptosis
Apoptosis, also termed programmed cell death, is necessary
for the maintenance of normal tissue homeostasis. Impaired
apoptosis has been associated with hyperproliferation and
tumorigenesis. Induction of apoptosis is accompanied by
certain morphological and molecular changes in the cell,
like DNA fragmentation, cleavage of caspases and caspase
substrates, and breakdown of mitochondrial transmem-
brane potential (Fig. 3). Resveratrol has been demonstrated
to induce apoptosis in a number of cell types [37, 75–77,
80, 82, 84–86, 92, 93]. The polyphenol not only induced
apoptosis in leukemic hematopoietic cells, but also in nor-
mal activated peripheral blood lymphocytes. It had no apop-
totic effect on nonactivated peripheral blood lymphocytes
[94]. In HL-60 promyelocytic leukemia cells resveratrol-
induced apoptosis was prevented by caspase inhibitors [95].
Resveratrol-induced apoptosis of CEM-C7H2 acute lym-
phoblastic leukemia cells was accompanied by cleavage of
caspase-6, -3, and -2, but seemed to be independent of cas-
pase-8 activation, because a caspase-8-deficient mutant
Jurkat cell line was sensitive to resveratrol-induced cell
death [96]. Activation of these caspases was inhibited by
overexpression of the oncogene Bcl-2 [97]. Overexpression
of Bcl-2 in U937 cells also attenuated apoptosis and pre-
vented cleavage of caspase-3 and PARP (poly ADP-ribose
polymerase) [98]. These findings could be confirmed by
Zhou et al. [99] demonstrating an upregulation of Bax as
well as a downregulation of Bcl-2 during resveratrol-
induced apoptosis. Another study could show that resvera-
trol-induced apoptosis is accompanied by induction of p53,
upregulation of Bax, activation of caspase 9, and decrease
in Bcl-2 levels [100].
In human prostate carcinoma cells (DU145) resveratrol
upregulated the Bax protein and mRNA expression in a
dose-dependent manner, whereas Bcl-2 and Bcl-xL levels
were not significantly affected. These results correlated
with an activation of caspase-3 and caspase-9 [84]. Other-
wise resveratrol-treated human liver cancer cells HepG2
and Hep3B had enhanced Bax expression but they were not
involved in the Fas/Apo-1 apoptotic signal pathway [82]. In
acute lymphoblastic leukemia cell lines, activation of cas-
pase-9 and depolarization of mitochondrial membranes
could be monitored after treatment with resveratrol [101].
Apoptosis can be induced by binding of proapoptotic pro-
teins (TNF-a, Fas ligand) to their receptors. TNF-a-induced
apoptosis, reactive oxygen species (ROS) generation and
lipid peroxidation were also inhibited by pretreatment with
5 lM resveratrol in U937 cells [60]. Clment et al. [102]
detected Fas-dependent apoptosis-signaling in HL-60 and
T47D cells, whereas Fas-independent apoptosis could be
demonstrated in CEM-C7H2 [96] and THP-1 monocytic
leukemia cells [103]. In a human colon cancer cell line
(SW480) resveratrol-induced apoptosis was also not
mediated directly through modulation of Fas/FasL interac-
tion, but was attributable to caspase activation and in-
creased accumulation of Bax and Bak [104]. High levels of
p53 expression in cells with fractional DNA content, i. e., in
apoptotic cells, strongly suggests that their apoptosis may
be associated with upregulation of p53 [75]. Furthermore,
Huang et al. [105] demonstrated that induction of apoptosis
in JB6 mouse epidermal cells is dependent on the presence
of the tumor suppressor p53. In HepG2 cells also a p53-
dependent pathway involving an increased expression of
Bax and upregulation of p21 was suggested [82]. In thyroid
cancer cells (BHP 2–7, BHP 18–21, FTC 236, and FTC
238) the apoptosis induced by resveratrol was inhibited by
p53 antisense oligonucleotide transfection or by addition of
the p53 inhibitor pifithrin-a [106]. In DU 145 prostate can-
cer cells resveratrol-induced apoptosis was also inhibited
by pifithrin-a. In addition, it was demonstrated that overex-
pression of p53 led to a higher apoptotic response [107]. In
contradiction to these results induction of apoptosis by
resveratrol has been shown in cell types deficient of func-
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Figure 3. Apoptosis and possible stimulatory pathways by
resveratrol. Resveratrol was shown to activate pro-apoptotic
caspases-6, -3, and -9 but seems to be partly independent of
caspase-8 activation. It also leads to an induction of tumor
suppressor p53 and Bax as well as an inhibition of Bcl-2. Addi-
tionally, resveratrol leads to an upregulation of pro-apoptotic
NAG-1. DIL, death-inducible ligands; NAG-1, NSAID-activated
gene; CAD, caspase-activated Dnase; ICAD, inhibitor of CAD.
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tional p53 [37, 108]. In the colorectal cancer cell line HCT-
116, which possesses wild-type p53, apoptosis occurs after
incubation with resveratrol via a p53-independent mechan-
ism [109]. The MAPK activation by resveratrol was found
to upregulate p53 in mouse epidermal JB6 cells [110, 111].
In thyroid cancer cells, apoptosis, c-Fos, and p53 induction
induced by resveratrol were blocked by the MEK inhibitor
PD98059 [106]. In DU 145 cells, Ser15 phosphorylation of
p53 by resveratrol was also blocked by PD98059 [107].
Resveratrol induced NAG-1 (NSAID-activated gene),
which has been demonstrated to induce apoptosis in the col-
orectal cancer cell line HCT-116 and the osteosarcoma cell
line U2OS. NAG-1 induction was dependent on the pre-
sence of wild-type p53 which has been shown to activate
the promoter of NAG-1 [112]. Further studies suggest that
an involvement of the pRb-E2F/DP pathway is suggested as
an important contributor of resveratrol-mediated cell cycle
arrest and apoptosis [85].
The synthetic resveratrol analog 3,4,5,49-tetrahydroxystil-
bene induced DNA fragmentation in SV40 transformed
WI38 lung fibroblasts, but not in normal WI38 cells. This
apoptosis induction was accompanied by increased p53 and
Bax expression, enhanced p53-binding to the bax promoter,
and decreased Bcl-xL, Bcl-xS, Bcl-2 expression. In addi-
tion, mRNA levels of BRCA1, BRCA2, and COX-2 were
diminished [113]. Another analog, 3,5,29,49-tetramethoxy-
trans-stilbene, was shown to induce the accumulation of
cellular DNA contents in the sub-G0 phase of the cell cycle
in a time-dependent manner, wheras the morphological
changes were consistent with an apoptotic process [114].
The natural occuring resveratrol analog piceatannol
(3,5,39,49-tetrahydroxy-trans-stilbene; PICE) was also
shown to be a potent inducer of apoptosis in human SK-
Mel-28 melanoma cells [115].
3.4 Angiogenesis and invasion
Neovascularization and thus supply of tumors with nutri-
ents is essential for their growth. Endothelial cell migration
and proliferation are as necessary for this process as the
breakdown of existing basal membranes by matrix metallo-
proteinases (MMPs). These enzymes are also implicated in
tumor cell invasion, which is the first step of metastasis
development. Resveratrol was found to inhibit growth of
bovine aorta endothelial cells in a dose-dependent manner.
In addition, it suppressed migration of these cells in a
wound assay and endothelial tube formation in a collagen
matrix, which is considered to represent a marker for
neoangiogenesis [116]. Resveratrol inhibited invasion, but
not proliferation of the rat ascites hepatoma cell line
AH109A pretreated with hypoxanthine and xanthine oxi-
dase in a coculture model with mesothelial cells. Addition
of sera from rats fed with resveratrol instead of calf serum
also inhibited invasion, but not proliferation of AH109A
cells, demonstrating a role for resveratrol in ROS-induced
cell invasion [117]. Resveratrol also inhibited the growth of
FGF-2-stimulated bovine capillary endothelial cells and
induced avascular zones in developing chick chorioallan-
toic membranes in a dose-dependent manner. Corneal neo-
vascularization induced by vascular endothelial growth fac-
tor (VEGF) and FGF-2 in mice was suppressed by oral
administration of resveratrol. The inhibiting effects of
resveratrol on angiogenesis were confirmed in a mouse skin
model, where delayed wound healing could be demon-
strated [45]. Resveratrol inhibited capillary-like tube for-
mation of human umbilical vein cells (HUVEC) and inhib-
ited the binding of VEGF to HUVEC [53]. VEGF expres-
sion did not significantly change when rat RT-2 glioma cells
were treated with low-dose resveratrol, but it was sup-
pressed when they were treated with 10, 25, or 100 lM
resveratrol [118]. Although resveratrol did not affect HIF-
1a mRNA levels in human ovarian cancer cells, it did dra-
matically inhibit both basal-level and growth factor-
induced HIF-1a protein expression in the cells as well as
VEGF expression [119]. Furthermore, resveratrol abolished
VEGF-induced VE-cadherin tyrosine phosphorylation and
redistribution and Src activity in HUVEC [120]. In contrast
to these findings, resveratrol did not inhibit invasion of the
murine melanoma cell line B16-BL6, as determined in a
Boyden chamber invasion assay [121].
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